GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Gastroenterol Clin N Am
31 (2002) 1145–1181

Cumulative Subject Index to Volume 31

Volume 31

March	INFLAMMATORY BOWEL DISEASE, pages 1–384
June	CLINICAL MANAGEMENT OF PREMALIGNANT DISORDERS OF THE GASTROINTESTINAL TRACT, pages 369–700
September	RADIOLOGIC IMAGING IN GASTROENTEROLOGY, pages 701–924
December	COLORECTAL CANCER PREVENTION AND DETECTION, pages 925–1181
December	NEW FRONTIERS IN GASTROESOPHAGEAL REFLUX DISEASE, pages S1–S120

Note: Page numbers of article titles are in **boldface** type.

A

Abdomen, postoperative distention of, computed tomography in, 795, 797–798

Aberrant crypt foci, colonic, 410–411, 965–967

Ablative techniques, for Barrett's esophagus, 454, 490–494

Abscess
  in inflammatory bowel disease, 109–110, 113, 260, 338–339
  liver, ultrasonography in, 816

Acetylation, histone, defects of, in carcinogenesis, 388–389

Acid-suppressant drugs
  esophageal adenocarcinoma risk from, 434–435
  for Barrett's esophagus, 481–484

ACTH (adrenocorticotropic hormone), for ulcerative colitis, 151

Addressins, in mucosal immunity, 79, 86

Adenocarcinoma
  esophageal. *See* Esophagus, adenocarcinoma of.
  gastric
    adenoma transformation into, 406
    versus esophageal adenocarcinoma, 426–427
  pancreatic, MRCP in, 722–724
  pancreatic duct, ultrasonography in, 826
  small intestinal, 408
    in celiac disease, 628–629
    in Crohn's disease, 631–632

Adenoma(s)
  colonic. *See* Colon, adenomas of.
  definition of, 396
  gastric, 405–406
  hepatocellular, imaging of, 773
  pancreatic, computed tomography in, 901
  small intestinal, 407–408

Adenoma–carcinoma continuum, 395–396

Adenomatous dysplasia, classical, esophageal, 401–402

Adenomatous polyposis, familial. *See* Familial adenomatous polyposis.

Adhesion molecules, inhibitors of, for inflammatory bowel disease, 86

Adhesions, in Crohn's disease, 172

Adhesive obstruction, of small intestine, 791–793

Adrenocorticotropic hormone, for ulcerative colitis, 151

Aflatoxin exposure, hepatocellular carcinoma risk in, 647

Age factors, in inflammatory bowel disease, 10–11

0889-8553/02/$ – see front matter © 2002, Elsevier Science (USA). All rights reserved.
PII: S0889-8553(02)00124-3

Alcohol consumption
disease risk in
Barrett's esophagus, 448–449
colorectal cancer, 596–597, 931
hepatocellular carcinoma, 647
pancreatic cancer, 673
inflammatory bowel disease and, 30

Alpha-1-antitrypsin deficiency, hepatocellular carcinoma in, 648

Alpha-fetoprotein, in hepatocellular carcinoma, 650–651

Amebic abscess, of liver, ultrasonography in, 816

American Cancer Society, screening guidelines of, 370

Aminopeptidase-N, in esophageal adenocarcinoma, 471

Aminosalicylates
for collagenous colitis, 299
for colorectal cancer prevention, 1139–1141
for Crohn's disease, 168
maintenance, 191
perineal, 194
for inflammatory bowel disease, in pregnancy, 269
for ulcerative colitis, 147–150
distal, 186–187
in pancolitis, 187
in proctitis, 185–186

Amitriptyline, for functional bowel disease, 354

Amsterdam criteria, for hereditary nonpolyposis colorectal cancer, 544, 571

Amyloidosis, of kidney, in inflammatory bowel disease, 319

Anal intraepithelial neoplasia, 413–414

Anemia, in inflammatory bowel disease, 317–318

Aneuploidy, DNA, in esophageal adenocarcinoma, 469–470

Angiography, for hemorrhage location, 702, 708

Ankylosing spondylitis, in inflammatory bowel disease, 313

Annular pancreas, MRCP in, 744

Anorectal pain, functional, with inflammatory bowel disease, 350

Antibiotics
for Crohn's disease, 168, 170, 190
for inflammatory bowel disease, 53–55, 269
for percutaneous cecostomy, in pediatric patients, 921
for ulcerative colitis, 152–153

Antibodies, radiolabeled, in positron emission tomography, 863–865

Anticholinergic agents
esophageal adenocarcinoma risk from, 434
lower esophageal sphincter function and, S23–S24, S113–S114

Antidepressants, for functional bowel disease, 354–355

Antidiarrheal agents, for functional bowel disease, 353–354

Antigen(s), intestinal mucosal permeability to, in inflammatory bowel disease, 46, 48–49

Antigen-presenting cells, recognition of, by T lymphocytes, 83–84

Antihypertensive drugs, esophageal adenocarcinoma risk from, 452

Antineutrophil cytoplasmic antibody
in inflammatory bowel disease, 141–142
in primary sclerosing cholangitis, 330–331

Antioxidants, dietary. *See* Vitamin C; Vitamin E.

Antireflux mechanisms, defects of, GERD in, S36–S39

Antireflux surgery
for Barrett's esophagus, 455, 482–484
for GERD, S90–S101
advantages of, S90–S92
laparoscopic, S91–S94
opposition to, S92–S94
postoperative problems in, S93, S97–S101
success in, S94–S97
versus medical therapy, S92–S94
revision of, S100–S101

Antispasmodic agents, for functional bowel disease, 354

Antrum, gastritis of, 504

Anus, dysplasia of, 412–414

APC gene, mutations of, 384–385

in colorectal cancer, 952–953
in esophageal adenocarcinoma, 464–465
in familial adenomatous polyposis, 538–541, 950, 960, 962, 1114–1117
in Gardner's syndrome, 1115
in inflammatory bowel disease, 554–556
murine models of, 1007–1008

Aphthous ulcers, in Crohn's disease, 101–103, 121–122, 136–137

Apoptosis
defects of, in esophageal adenocarcinoma, 466–467
Helicobacter pylori effects on, 526–527
in normal growth and proliferation, 380–382

Appendectomy, inflammatory bowel disease and, 26

Appendicitis, ultrasonography in, 828–829

Argon plasma coagulation, for Barrett's esophagus, 491–492

Arthropathy, in inflammatory bowel disease, 53, 311–313

Aspirin, for colorectal cancer prevention, 604–606, 932–933, 981–982, 985–986, 993, 1139–1141
cost-effectiveness of, 16–17, 1077

Asthma, gastroesophageal reflux disease and, S95–S96

Atropine, lower esophageal sphincter function and, S23–S24, S113–S114

Autoantibodies, detection of, in inflammatory bowel disease, 141–142

Autoimmune disorders
collagenous colitis with, 294, 297
inflammatory bowel disease with, extraintestinal manifestations and, 310
lymphocytic colitis with, 300–301

Autoimmune gastritis, 505, 507

Avascular necrosis, in inflammatory bowel disease, 314–315

Axin protein, in carcinogenesis, 384–385

Azathioprine
for Crohn's disease, 170–171, 173, 175
gastroduodenal, 189
intestinal, 190–191
oral, 189
perineal, 195
steroid-refractory, 192
for inflammatory bowel disease
in pediatric patients, 283–285
in pregnancy, 269–270
monitoring of, 284–285
safety of, 285
for ulcerative colitis, 153
in pancolitis, 187
steroid-refractory, 188–189

B

B lymphocytes, lamina propria, in mucosal immunity, 81–82

Backwash ileitis, in ulcerative colitis, 95, 123, 139

Baclofen, lower esophageal sphincter function and, S16–S17, S114–S116

Balloon dilation, of strictures
esophageal, in pediatric patients, 918–919
in inflammatory bowel disease, 128–129
in primary sclerosing cholangitis, 334–336

Balsalazide, for ulcerative colitis, 148–149, 187

Bamboo spine, in inflammatory bowel disease, 313

Bannayan-Riley-Ruvalcaba syndrome
clinical features of, 1108, 1122
genetics of, 1108

Barium studies
in Crohn's disease, 101–105
in ulcerative colitis, 94–96
of small intestine. *See* Enteroclysis.

Barrett's esophagus, 399, 432–433, **441–460, 481–497,** S1, S3–S7
adenocarcinoma development from, 431–432, 441–443, **461–479**
APC gene in, 464–465
apoptosis defects in, 466–468
Bax protein in, 467
Bcl-2 protein in, 467
cell-cycle regulators in, 462–464
chromosomal abnormalities in, 469
cyclooxygenase-2 in, 466
cytochromes p450 in, 471–472
DNA ploidy and aneuploidy in, 469–470
E-cadherin/catenin complex in, 464–465

Barrett's esophagus (*continued*)
c-erbB-2 protein in, 463–464
Fas receptor protein in, 466–467
growth factors and receptors in, 463
Her-2/neu protein in, 463–464
intestinal differentiation markers in, 470–471
Ki-67 antigen in, 462
microsatellite instability in, 470
c-myb protein in, 472
p16 gene mutation in, 462–463
p53 gene mutation in, 467–468
proliferation regulators in, 462–464
proliferative cell nuclear antigen (PCNA) in, 462
ras genes in, 468–469
retinoblastoma gene in, 464
retinoic acid receptors in, 472
sequence of, 472–473
telomerase in, 472
cancer risk in, S71–S72
extent of, prognosis and, 449–450
histology of, 399–404
in gastroesophageal reflux disease, 399
incidence of, 442, 461
progression of, 404
regression of, 455–456
risk factors for, 432–433, 444–456
alcohol consumption, 448–449
columnar epithelial regression, 455–456
demographic, 445
dietary, 450–451
dysplasia presence, 452–453
extent, 449–450
medical interventions, 453–455
medications, 452
obesity, 450–451
racial, 445–446
scleroderma, 452
smoking, 447–448
socioeconomic, 446–447
symptom severity, 444–445
screening for, 372
surveillance in, 485–490
treatment of, 453–455
acid control in, 481–484
antireflux surgery in, S93, S96
endoscopic ablative therapy for, 490–494

Barrett's esophagus–associated polypoid dysplasia, 399

Bax protein, in esophageal adenocarcinoma, 467

Bcl-2 protein, in esophageal adenocarcinoma, 467

Bear claw ulcers, in inflammatory bowel disease, 122

Behavioral therapy, for functional bowel disease, 355

Benzodiazepines, for GERD, case studies of, S78–S83

Beta-carotene, for colorectal cancer prevention, 598–599, 603

Betel nut chewing, inflammatory bowel disease and, 25

Bethesda criteria, for hereditary nonpolyposis colorectal cancer, 571

Bifidobacteria, for inflammatory bowel disease, 55, 211–212

Biliary cirrhosis, primary, in inflammatory bowel disease, 338

Biliary tract
cancer of, endoscopic ultrasonography in, 878
congenital variants of, MRCP in, 737–739
cystadenoma of, ultrasonography in, 823–824
disease of, in inflammatory bowel disease. *See* Hepatobiliary disease, in inflammatory bowel disease; Primary sclerosing cholangitis.
injuries of, MRCP in, 743
obstruction of, ultrasonography in, 822
stones in
MRCP in, 741–743
ultrasonography in, 822
strictures of, MRCP in, 739–740
tumors of, MRCP in, 739–740
ultrasonography of, 821–824

Biopsy
in inflammatory bowel disease, 122–123, 142, 244–247
in primary sclerosing cholangitis, 332
in rectal cancer, 1098–1099
liver, percutaneous, imaging for, in pediatric patients, 923–925
pancreas, endoscopic ultrasonographic guidance in, 876–877

Birth order, inflammatory bowel disease and, 33

Bismuth subsalicylate, for collagenous colitis, 299

Bladder, fistulas of, in Crohn's disease, 109

Bleeding. *See* Hemorrhage.

Bloating, after antireflux surgery, S100

Blood disorders, in inflammatory bowel disease, 308, 317–318

BMPR1A gene, mutations of, in juvenile polyposis syndrome, 1120–1122

Body mass index, esophageal adenocarcinoma risk and, 433

Body weight
  colorectal cancer risk and, 590–592
  esophageal adenocarcinoma risk and, 433

Bone disorders, in inflammatory bowel disease, 206–207, 313–315

Bougienage, for esophageal stricture, in pediatric patients, 917–918

Brain, in lower esophageal sphincter control, **S11–S20**
  agents acting on, S16–S17
  vagovagal reflexes in, S12–S16

BRCA2 gene and product, mutations of, in pancreatic cancer, 669–670

Breast-feeding, inflammatory bowel disease and, 31, 268–271

Brooke ileostomy, with total proctocolectomy, for ulcerative colitis, 224–225

Budd-Chiari syndrome, ultrasonography in, 814–815

Budesonide
  for collagenous colitis, 299
  for Crohn's disease, 168–170, 174–175
    intestinal, 190
    maintenance, 191
    recurrent, 195
  for ulcerative colitis, 186

Buffering, in esophageal epithelial resistance, S40–S42

Bulking agents, for functional bowel disease, 353

C

CagA protein, as *Helicobacter pylori* virulence factor, 519, 525–526

Calcium supplementation
  for colorectal cancer prevention, 576–577, 597, 603, 929, 981–982, 985–986
  for inflammatory bowel disease, 208, 314–315

Cancer. *See also specific locations, e.g.,* Colorectal cancer.
  biliary tract, endoscopic ultrasonography in, 878
  colorectal. *See* Colorectal cancer; Rectal cancer.
  early detection of, **369–378**
    in elderly persons, 372–373
    programs for, 369–372
  esophageal
    endoscopic ultrasonography in, 880–882
    positron emission tomography in, 854–858
    risk of, in gastroesophageal reflux disease, S69–S72
  gallbladder, ultrasonography in, 820, 823
  gastric
    endoscopic ultrasonography in, 879
    positron emission tomography of, 863
  genetics of. *See* Genetic factors, in cancer.
  in Crohn's disease, 114, 248–250, **551–564,** 1142–1143
    clinical features of, 557–558
    endoscopic surveillance for, 125–126
    molecular pathways of, 552–557
    risk factors for, 248–249, 558–559
    screening for, 250
    surveillance for, 249–250, 559–561
  in inflammatory bowel disease, **551–564**
    at stricture sites, 558
    biopsy in, 129
    clinical features of, 557–558
    familial, 559
    in perianal fistulas, 558–559
    molecular pathways of, 552–557
    primary sclerosing cholangitis with, 559
    risk factors for, 558–559
    surgical preventive measures for, 221
    surveillance in, 559–561, 573–574
    treatment effects on, 559
    versus duration and extent, 558
  in primary sclerosing cholangitis, 336–337
  in ulcerative colitis, 100, 238–248, **551–564**
    adenoma management and, 246–247
    clinical features of, 557–558

Cancer (*continued*)
dysplasia developing into, 245–246
family history of, 242
left-sided, 238–240
molecular pathways of, 552–557
pancolonic, 238–239
prevention of, 1134–1142
primary sclerosing cholangitis and, 241–242
risk factors for, 558–559
surgical preventive measures for, 221
surveillance for, 242–245, 559–561, 1135–1139
versus age of onset, 240–241
versus duration of disease, 240
versus severity, 240
with ileal pouch, 247–248
liver. *See* Hepatocellular carcinoma; Liver, cancer of.
lung, staging of, endoscopic ultrasonography in, 879–880
molecular biology of, 373–375
pancreatic. *See* Pancreas, cancer of.
prevention of, 375–376. *See also* Colorectal cancer, prevention of.
rectal. *See* Colorectal cancer; Rectal cancer.
screening and surveillance for, 369–373
colorectal. *See* Colorectal cancer, screening and surveillance for.
esophageal, 485–490
gastric, 510
hepatocellular carcinoma, 649–654
pancreatic, 674–675

Candidate gene studies, of inflammatory bowel disease, 67–68

Cannabinoids, action of, on lower esophageal sphincter, S17

Carbohydrates, types of, colorectal cancer risk and, 593–594

Carcinogenesis, **379–394**
chemoprevention and, 971–976
clinical applications of, 389–390
colorectal, 543–546, 556, 579
epigenetic phenomena in, 388–389
esophageal, 435–436
gastric, 499, 503, **517–535**
genetics of, 384–389
mismatch repair defects in. *See* Mismatch repair, defects of.
p53 gene mutations in, 387
pancreatic, 668–671
principles of, 383–389
Ras proteins in, 385–386
Smad proteins in, 386–387
transforming growth factor-β in, 386–387
versus normal cell growth and proliferation, 380–383
Wnt signaling pathway in, 384–385

Carcinoma. *See* Adenocarcinoma; Hepatocellular carcinoma; Stomach, carcinoma of.

Cardiovascular disorders, in inflammatory bowel disease, 309, 319

Caroli disease, ultrasonography in, 824

Carotenoids, for colorectal cancer prevention, 598–599, 603

Cataract, in inflammatory bowel disease, corticosteroid-induced, 317

β-Catenin, in carcinogenesis, 384–385
colorectal, 556
esophageal, 464–465

Catheters, for enteroclysis, 719–721, 725

CDX1 protein, in esophageal adenocarcinoma, 471

Cecostomy, percutaneous, imaging for, in pediatric patients, 920–923

Celecoxib, for colorectal cancer prevention, 604, 606, 932–933, 981–982, 986, 993

Celiac disease, small intestinal cancer in, 627–631

Celiac plexus neurolysis, endoscopic ultrasonography in, 882–883

Cell(s), normal growth and proliferation of, versus carcinogenesis, 380–383

Central nervous system, in lower esophageal sphincter control, **S11–S20**
agents acting on, S16–S17
vagovagal reflexes in, S12–S16

CFTR gene and product, mutations of, in pancreatic cancer, 670

Chemokines, in mucosal immunity, 84

Chemoprevention, of colorectal cancer, **971–999**. *See also specific agents.*

Chemotherapy, for rectal cancer, staging after, 845

Chloroma, of liver, ultrasonography in, 818

Cholangiocarcinoma
in primary sclerosing cholangitis, 336–337

intrahepatic, imaging of, 773–774
ultrasonography in, 823

Cholangiography
in biliary strictures, 739–740
in primary sclerosing cholangitis, 331–332, 334–336

Cholangiopancreatography, magnetic resonance. *See* Magnetic resonance cholangiopancreatography.

Cholangitis
primary sclerosing. *See* Primary sclerosing cholangitis.
sclerosing, MRCP in, 740
ultrasonography in, 822–823

Cholecystitis, ultrasonography in, 820–821

Cholecystokinin, lower esophageal sphincter function and, S24, S112–S113

Choledochal cysts
MRCP in, 739
ultrasonography in, 824

Choledocholithiasis
MRCP in, 739, 741–743
ultrasonography in, 822, 878–879

Cholelithiasis, in primary sclerosing cholangitis, 338

Choline, in positron emission tomography, 855–856

Chromosomal abnormalities, in esophageal adenocarcinoma, 469

Cigarette smoking. *See* Smoking.

Ciprofloxacin
for Crohn's disease, 168, 174
in peritonitis, 191
intestinal, 190
for inflammatory bowel disease, 53–55, 269
for ulcerative colitis, 152–153

Cirrhosis
liver
as hepatocellular carcinoma precursor, 642–643
ultrasonography in, 812–813
primary biliary, in inflammatory bowel disease, 338

Clarithromycin, for inflammatory bowel disease, 54

Clostridium difficile infections, inflammatory bowel disease exacerbation in, 52

Coagulopathy, in inflammatory bowel disease, 318

Cobblestone appearance, in Crohn's disease, 103

Coffee, inflammatory bowel disease and, 30

Cognitive-behavioral therapy, for functional bowel disease, 355

Coil embolization, endovascular, for gastrointestinal hemorrhage, 703, 711

Colectomy
for familial adenomatous polyposis, 541–542, 1119
for hereditary nonpolyposis colorectal cancer, 546–547, 572, 1113
for inflammatory bowel disease, 560, 1137, 1139
for juvenile polyposis syndrome, 1123
for Peutz-Jeghers syndrome, 1126
for ulcerative colitis
subtotal, with ileostomy, 222–223
with ileorectal anastomosis, 223–224

Colitis
atypical, **293–305**
collagenous, 294–300
lymphocytic, 300–302
microscopic, in inflammatory bowel disease, 312–313
ulcerative. *See* Ulcerative colitis.

Collagenous colitis, 294–300
clinical features of, 294
conditions associated with, 294
diagnosis of, 294–295
endoscopy in, 295
epidemiology of, 294
histology of, 295–297
pathogenesis of, 297–298
prognosis for, 300
treatment of, 297–300

Collis-Nissen gastroplasty, for GERD, S95–S96

Colon
aberrant crypt foci in, 965–967
adenomas of, 408–410, 606–607. *See also* Familial adenomatous polyposis.
in ulcerative colitis, 246–247
serrated, 964–965
cancer of. *See* Colorectal cancer.
diverticulitis of
computed tomography in, 795
ultrasonography in, 829
dysplasia of
adenomatous, 408–410

Colon (*continued*)
in aberrant crypt foci, 410–411
in hyperplastic polyps, 410
in juvenile polyps, 410
in ulcerative colitis, 242–246
inflammatory bowel disease and, 411–412, 1136–1137
hemorrhage of, endovascular intervention for, 708–713
mural thickening of
in Crohn's disease, 106–107, 111–114
in ulcerative colitis, 96–98
narrowing and shortening of
in inflammatory bowel disease, endoscopic treatment of, 128–129
in ulcerative colitis, 95–96
normal cell growth and proliferation in, 381–383
obstruction of, computed tomography in, 798–805
polyps of. *See also* Familial adenomatous polyposis; Juvenile polyposis syndrome.
dysplasia in, 410
in virtual colonoscopy, 1054–1055
removal of, 566–567, 1137–1138
resection of. *See also* Colectomy.
in Crohn's disease, 259–260
strictures of, in Crohn's disease, 103–104, 261
volvulus of, computed tomography in, 803

Colonocytes, genetic testing of, in colorectal cancer, 579

Colonography, computed tomography. *See* Virtual colonoscopy.

Colonoscopy
in cancer screening and surveillance, 573, **1031–1044,** 1079–1082
advantages of, 568–569
benefits of, versus risks, 1039–1040
colonoscopy for, 1135–1139
cost-effectiveness of, 1023–1024, 1035, 1037, 1077, 1079–1082
demand for, 1037–1039
evolution of, 1031–1034
hereditary nonpolyposis colorectal, 542, 572
implementation of, 1037–1040
in familial adenomatous polyposis, 1117–1118
in hereditary nonpolyposis colorectal cancer, 1112–1113
in inflammatory bowel disease, 1135–1139
in juvenile polyposis syndrome, 1122–1123
in Peutz-Jeghers syndrome, 1125–1126
in positive sigmoidoscopy results, 1039
limitations of, 1135–1136
mortality in, 1040
popular support for, 1032
recommendations for, 1035–1036, 1040
resources for, 1039
risks of, versus benefits, 1039–1040
status in 2002, 1034–1037
tailored decision-making about, 1040
versus sigmoidoscopy, 1021–1025
with symptoms, 574–575
in collagenous colitis, 295
in familial adenomatous polyposis, 540–541, 1117–1118
in inflammatory bowel disease, 120–126, 559–560
diagnostic, 120–122
for cancer surveillance, 125–126, 242–246, 249–250, 1135–1139
in extent evaluation, 122–124
postoperative, 124–125
preoperative, 124
in lymphocytic colitis, 301
in ulcerative colitis, 100
incomplete, virtual colonoscopy after, 757–758, 1050–1051
versus virtual colonoscopy, 1056–1057
virtual. *See* Virtual colonoscopy.
with polypectomy, 566–567

Colorectal adenomata and carcinoma syndrome, 1126

Colorectal cancer
chemoprevention of, **971–999**
diagnosis of, molecular genetic tests for, 389–390
distal, endoscopic detection of, 1023
DNA methylation defects in, 945–958
epidemiology of, 537, 565–566, 925–926, 1018
epigenetic changes in, 945–958
family history of, screening in, 570–572
gene silencing in, 946–947
gene therapy for, 390
genetic factors in. *See* Genetic factors, in cancer, colorectal.
geographic factors in, 588–589
hereditary, **537–549**. *See also specific*

syndromes, e.g., Familial adenomatous polyposis.
atypical, 1126
preventive management in, **1107–1131**
in inflammatory bowel disease. *See* Cancer, in Crohn's disease; Cancer, in ulcerative colitis.
metastasis from, molecular markers for, 954
microsatellite instability in, 948, 950, 962
mismatch repair defects in, 388
mortality in, 587
obstruction in
computed tomography in, 799–802
virtual colonoscopy in, 757–758
positron emission tomography in, 850–854
precursors of, **959–970**. *See also* Familial adenomatous polyposis; Juvenile polyposis syndrome; Colon, polyps of.
aberrant crypt foci, 965–967
epigenetic changes in, 949–950
histologic, 408–414
in defective DNA mismatch repair pathway, 960–964
serrated pathway in, 964–965
prevention of, 577, **587–623, 925–943, 971–999**. *See also* Colorectal cancer, screening and surveillance for.
agents for, 977–987
aspirin for, 932–933, 981–982, 985–986, 993, 1139–1141
barriers to, **1061–1068**
extrinsic, 1065–1066
intrinsic, 1063–1065
carcinogenesis and, 971–972
categories of, 972–976
clinical research infrastructure for, 989
clinical trials of, 609–611, 977–994
cost-effectiveness of, **1069–1091**
aspirin, 16–17, 1077
chemoprevention, 1077, 1084–1085
colonoscopy, 1023–1024, 1077, 1079–1082
computed tomography, 1082–1084
fecal occult blood tests, 1071–1078
limitations of, 1087–1089
magnetic resonance imaging, 1082–1084
principles of, 1069–1071
sigmoidoscopy, 1023–1024, 1077, 1082
dietary, 575–577, 588–604, 927–928, 984–985
alcohol intake limitation for, 596–597, 931
calcium supplementation for, 576–577, 597, 603, 929, 981–982, 985–986
carbohydrate type and, 593–594
carotenoids for, 598–599, 603
curcumin for, 609
ecologic studies of, 589
efficacy of, 609–611
evidence for, 588–589
fat intake limitation for, 594, 602
fiber for, 575–576, 594–595, 602, 928–929
folate for, 576, 599–600, 930–931, 1141–1142
fruits and vegetables for, 595–596, 602, 928–929
intervention trials of, 601–604
selenium supplementation for, 598, 603–604, 930
vitamins for, 577, 597–598, 600, 602–603, 929–931, 984, 1141–1142
difluoromethylornithine for, 608
dysplasia management in, 1136–1137
efficacy of, 610–611
exercise for, 926–927
folate supplementation for, 576, 599–600, 930–931, 1141–1142
hormone replacement therapy for, 933
3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors for, 608–609
imaging in, 578–579
immunotherapy for, **1001–1013**
in familial adenomatous polyposis, 986, 1118–1119
in hereditary colorectal cancer syndromes, **1107–1131**
in hereditary nonpolyposis colorectal cancer, 1113
in high-risk persons, 981, 986
in inflammatory bowel disease, **1133–1144**
in juvenile polyposis syndrome, 1123

Colorectal cancer (*continued*)
in Peutz-Jeghers syndrome, 1126
in vivo models of, 976–977
insulin resistance control in, 927
molecular targets of, 977, 982–983, 990
nonsteroidal anti-inflammatory drugs for, 604–607, 1139–1141
obesity reduction for, 926–927
original intent of, 994
physical activity for, 592
primary, 610–611, 974
problems with, 987–989
prospects for, 989–994
public demand for, 992
regulatory approval standards in, 989
salicylates for, 1139–1141
secondary, 610–611, 974
smoking cessation for, 601, 931–932
stool genetic testing for, 579
tertiary, 974, 976
therapeutic index in, 987–989
ursodeoxycholic acid for, 608, 1142
vitamins for, 577, 597–598, 600, 602–603, 929–931, 984
weight reduction for, 590–592, 926–927
prognosis of, molecular genetic tests for, 390
proximal, endoscopic detection of, 1023
risk of
in inflammatory bowel disease, 1133–1134
modifiable. *See* Colorectal cancer, prevention of.
screening and surveillance for, 370–371, 565–574, 971–972, 974
barriers to, **1061–1068**
colonoscopy in. *See* Colonoscopy, in cancer screening and surveillance.
compliance with, 1136
computed tomography for, 1082–1084
cost-effectiveness of, 1023–1024, 1035, 1037, **1069–1091**
costs of, 567
definition of, 1015
detection sensitivity and, 566
fecal occult blood test for, 1017–1020, 1070–1079
hereditary nonpolyposis, 542, 544–545, 1112–1113
in adenomatous polyp history, 569–570, 573
in average risk, 567–569
in cancer history, 570–573
in familial adenomatous polyposis, 1117–1118
in increased risk, 569–574
in inflammatory bowel disease, 573–574
in juvenile polyposis syndrome, 1122–1123
in Peutz-Jeghers syndrome, 1125–1126
in suggestive cancer symptoms, 574–575
intervals for, 569, 1026
limitations of, 1015–1016
magnetic resonance imaging for, 1082–1084
methods for, 567–569
methylation changes in, 953–954
patient acceptability of, 566
patient selection for, 567–574
prevalence and, 565–566
purpose of, 1016
recommendations for, 1035–1036
sigmoidoscopy for, **1015–1029,** 1082
strategy for, 1137–1139
treatment options and, 566–567
virtual colonoscopy for. *See* Virtual colonoscopy.
staging of, endoscopic ultrasonography in, 874–875
symptoms of, colonoscopy in, 574–575
Wnt signaling pathway in, 384–385

Comb sign, in Crohn's disease, 108, 113

Common variable immunodeficiency, inflammatory bowel disease and, 277

Computed tomography
curved planar reformations in, 890–892
in colorectal cancer prevention, cost-effectiveness of, 1082–1084
in colorectal cancer screening, 578
in Crohn's disease, 105–112
in enteroclysis, 729–731
in hepatocellular carcinoma, 652–653
in intestinal obstruction, **779–807**
background of, 779–781
colon, 794–805
small, 782–794
technique for, 781–782
in liver cancer. *See* Liver, cancer of, computed tomography in.
in pancreatic tumors, **889–906**
cystic, 901–905
ductal adenocarcinoma, 892–897
neuroendocrine, 897–901

techniques for, 889–892
in ulcerative colitis, 96–97
in virtual colonoscopy. *See* Virtual colonoscopy.
in volumetric imaging, of pancreatic tumors, 890
multidetector-row, in pancreatic tumors, 889–890
versus enteroclysis, 786

Condyloma acuminatum, as precursor lesion, 412–413

Congenital hyperinsulinism, diagnosis and treatment of, 926–932

Constipation, functional, with inflammatory bowel disease, 350–351

Contraceptives, oral, inflammatory bowel disease and, 26–28

Contrast agents
for ultrasound, 811
for virtual colonoscopy, 1051–1053

Copper accumulation, in Wilson disease, hepatocellular carcinoma in, 648–649

Corticosteroids. *See also specific drugs.*
for collagenous colitis, 299
for Crohn's disease, 169–170
for inflammatory bowel disease
bone metabolic disorders in, 207, 315
cataract due to, 317
dietary supplements with, 208
in pregnancy, 269
for ulcerative colitis, 150–152

Cost-effectiveness, of colorectal cancer prevention. *See* Colorectal cancer, prevention of, cost-effectiveness of.

Cowden syndrome
clinical features of, 1108, 1120–1121
genetics of, 1108

CpG islands, abnormal methylation of, in carcinogenesis, 388–389, 946–949, 951

Crail's syndrome, 539

Crohn's disease, 194–195
cancer in. *See* Cancer, in Crohn's disease.
cholelithiasis in, 338
clinical features of, in pediatric patients, 278–279
colitis in, treatment of, 190–191
computed tomography in, 794–795
diagnosis of, 256
endoscopic, 119–120, 126
in pediatric patients, 279–281
in pregnancy, 267–268
differential diagnosis of, 140
dysplasia in, 412
endoscopy in, 126
diagnostic, 119–124, 126
for disease extent evaluation, 122–124, 126
ileoscopy in, 127
in pouchitis, 129
postoperative, 124–125
preoperative, 124
small bowel, 127
therapeutic, 127–129
enteroclysis in, 722
environmental factors in, 276–277
appendectomy, 26
breast-feeding, 31
diet, 28–31
genetic factors interacting with, 67
hygiene, 31, 50
in pediatric patients, 276–277
nonsteroidal anti-inflammatory drugs, 32
occupation, 31–32
oral contraceptives, 26–28
seasons, 32
tobacco use, 21–25
epidemiology of, **1–20,** 63
age of onset, 10–11
challenges in, 1–2
ethnic differences in, 11–12
gender distribution in, 10
incidence of, 2–10
prevalence of, 2–10
racial differences in, 11–12
temporal trends in, 2–10
exacerbations of, enteric pathogens in, 52
extent of, endoscopic evaluation of, 122–124, 126
extraintestinal manifestations of. *See* Inflammatory bowel disease, extraintestinal manifestations of.
fertility in, 265–266
fistulas in, treatment of, 173–174, 194–195, 257–258, 260
functional bowel disease with. *See* Functional bowel disease.
gastroduodenal, 189
genetic factors in, **63–76,** 275–276, 310
ileitis in, 190–191
ileocolitis in, 190–191
ileoscopy in, 127
immunology of. *See* Immunology, of inflammatory bowel disease.
magnetic resonance imaging in, 280–281
metastasis from, 320
mild-to-moderate, 167–169

Crohn's disease (*continued*)
moderate-to-severe, 169–172
natural variation in, 138–139
obstruction in, 191
oral, 189
pathogenesis of, microbial factors in. *See* Microbial factors, in inflammatory bowel disease.
pathology of
in natural variation, 138–139
pseudopolyps, 139–140
quiescent, 139
treatment effects on, 140
versus ulcerative colitis, 133–137
perineal and perianal, 194–195, 261–262
peritonitis in, 191
pouchitis in, 51
pregnancy and, 266–271
pseudopolyps in, 139–140
quiescent, 139
radiography of, 101–114
barium studies, 101–105
computed tomography, 105–112
for disease activity evaluation, 111–114
in malignancy, 114
magnetic resonance imaging, 112, 114
ultrasonography, 110, 130
versus ulcerative colitis, 114–115
recurrence of
after ileostomy, 51
endoscopy in, 125–204–7
prevention of, 176–177
treatment of, 195, 262
severe-to-fulminant, 172–173
severity of, GETAID index for, 123–124
skip lesions in, 101, 121
small intestinal cancer in, 631–632
steroid-refractory, 170, 192–194
surgical treatment of, 172–173, 176–177, **255–263**
anatomic location and, 255–256
colonic, 261
diagnosis for, 256
indications for, 256–258
laparoscopic, 259–260
perianal, 261–262
preoperative evaluation and preparation for, 258–259
recurrent, 262
resection in, 259
technical aspects of, 259–262
with abscess, 260
with fistulas, 257–258, 260
with stricture, 261
treatment of, **167–184**
antibiotics for. *See* Antibiotics.
biologic agents for, 193–194
endoscopic, 127–129
for recurrence prevention, 176–177
immunomodulators in, 192–193, 282–287
in colitis, 190–191
in fistulas, 173–174, 194–195
in gastroduodenal involvement, 189
in ileitis, 190–191
in ileocolitis, 190–191
in obstruction, 191
in oral involvement, 189
in pediatric patients, 282–287
in perineal disease, 194–195
in peritonitis, 191
in pregnancy, 268–271
maintenance, 174–176, 191–192
mild-to-moderate, 167–169
moderate-to-severe, 169–172
monitoring of, 111–114
pathology modification in, 140
probiotics for, 55–56, 89
recurrent, 195
severe-to-fulminant, 172–173
steroid-refractory, 192–194
surgical, 172–173, 176–177, **255–263**
tumor necrosis factor inhibitors in, 86–88
upper tract, 169
upper tract, treatment of, 169
versus congenital immunodeficiency, 277–278
versus ulcerative colitis
endoscopic appearance in, 121–124
radiography of, 114–115

Crypt–villus axis, in intestinal cell migration, 382–383

Cryptitis, in ulcerative colitis, 134–136

Curcumin, for colorectal cancer prevention, 609

Cutaneous disorders, in inflammatory bowel disease, 308, 315–317, 320

Cyclooxygenase
in esophageal adenocarcinoma, 466
inhibitors of, for colorectal cancer prevention, 578, 604, 606–607, 1118–1119

Cyclosporine
for Crohn's disease, 173, 175
perineal, 195
steroid-refractory, 192

for inflammatory bowel disease, in pediatric patients, 286–287
for ulcerative colitis, 154–155, 188

Cyst(s)
choledochal
MRCP in, 739
ultrasonography in, 824
liver, ultrasonography in, 815–816
pancreatic
computed tomography in, 901–905
endoscopic ultrasonography in, 877
ultrasonography in, 826–828

Cystadenoma, biliary, ultrasonography in, 823–824

Cystic duct, variants of, MRCP in, 737–739

Cystic fibrosis, pancreatic cancer in, 666–667

Cytochromes P450, in esophageal adenocarcinoma, 471–472

Cytokines
in *Helicobacter pylori* infection, 521, 523–524, 526
in inflammatory bowel disease pathogenesis, 49–50
in mucosal immunity, 82–85
inhibitors of, for Crohn's disease, 193

Cytomegalovirus infections, inflammatory bowel disease exacerbation in, 52, 120–121

D

DCC (deleted in colon cancer) gene, mutations of, in inflammatory bowel disease, 554

Dendritic cells, in mucosal immunity, 81–84

Dermatologic disorders, in inflammatory bowel disease, 308, 315–317, 320

Des-gamma-carboxyprothrombin (DCP, PIVKA-II) measurement, in hepatocellular carcinoma, 651

Desmoid tumors, in familial adenomatous polyposis, 1114–1115

Diaphragm, contraction of, lower esophageal sphincter function and, S22

Diarrhea
functional, with inflammatory bowel disease, 351
in collagenous colitis, 294
in inflammatory bowel disease, treatment of, 353–354

Diazepam
for enteroclysis, 719
for GERD, case studies of, S78–S83

Dicyclomine, for functional bowel disease, 354

Diet
Barrett's esophagus and, 450–451
esophageal adenocarcinoma and, 433, 450–451
for cancer prevention, 375–376. *See also* Colorectal cancer, prevention of, dietary.
for celiac disease, 628
for Crohn's disease, 172
for functional bowel disease, 352–353
gastric cancer and, 503
inflammatory bowel disease and, 28–31
enteral, 208–209
parenteral, 210
pathogenic effects of, 203–204
perioperative, 210
recommendations for, 207–208
pancreatic cancer and, 674

Difluoromethylornithine, for colorectal cancer prevention, 608

Diphenoxylate, for functional bowel disease, 353–354

Diverticulitis
computed tomography in, 795
ultrasonography in, 829

DNA
aneuploidy of, in esophageal adenocarcinoma, 469–470
hypermethylation of
in carcinogenesis, 388–389
in colorectal cancer, **945–958**
as early event, 949–950
as molecular marker for cancer detection, 953–954
gene silencing and, 946–947
genetic changes and, 950–951
multiple gene involvement in, 951–953
target genes in, 947–949
ploidy of, in esophageal adenocarcinoma, 469–470
repair of, defects of, in carcinogenesis, 387–388, 960–964

DNA methyltransferase, defects of, 946

Doppler sonography, 810–811

Dorsal motor nucleus of the vagus, in lower esophageal sphincter control, S13, S15

Double halo sign, in ulcerative colitis, 96–97

DPC4 gene and product, mutations of, in pancreatic cancer, 669–670

Dysbiosis, in inflammatory bowel disease pathogenesis, 45–46

Dysphagia, after antireflux surgery, S98–S100

Dysplasia
  anal, 412–414
  characteristics of, 395–396
  classification of, 396
  colorectal
    adenomatous, 408–410
    in aberrant crypt foci, 410–411
    in hyperplastic polyps, 410
    in juvenile polyps, 410
    inflammatory bowel disease and, 411–412, 1136–1137
  definition of, 395
  diagnosis of, problems with, 396
  differential diagnosis of, 396
  esophageal
    glandular, 399–404, 452–453, 488–490
    squamous, 397–399
  gastric
    endocrine cell, 406–407
    epithelial, 404–406
  hepatic, as hepatocellular carcinoma precursor, 644–645
  high-grade, 396, 401–404, 488–490
  low-grade, 396, 401–404, 488–490
  small intestinal, 407–408

Dysplasia-associated lesions, 396
  colonic, 411
  in inflammatory bowel disease, 553, 560

E

E-cadherin
  in esophageal adenocarcinoma, 464–465
  in *Helicobacter pylori* infection, 526

Economic issues
  in colorectal cancer. *See* Colorectal cancer, prevention of, cost-effectiveness of.
  in gastroesophageal reflux disease, S68–S69

Educational level, Barrett's esophagus risk and, 446–447

Elderly persons, cancer screening in, 369–373

Electrocoagulation, multipolar, for Barrett's esophagus, 491

Embolization
  endovascular, for gastrointestinal hemorrhage, 703–713
  in liver biopsy, in pediatric patients, 923–924

Endocarditis, in inflammatory bowel disease, 53

Endocrine cell dysplasia, gastric, 406–407

Endoscopic ablative therapy, for Barrett's esophagus, 490–494

Endoscopic mucosal resection, for Barrett's esophagus, 493–494

Endoscopic retrograde cholangiopancreatography
  in biliary strictures, 739
  in choledocholithiasis, 742
  in pediatric patients, 908–909
  in primary sclerosing cholangitis, 331–332, 334–336
  in ulcerative colitis, 129–130

Endoscopic ultrasonography, **871–887**
  equipment for, 871–873
  in biliary neoplasms, 878
  in choledocholithiasis, 878–879
  in colorectal cancer staging, 874–875
  in esophageal carcinoma, 880–882
  in gastric cancer, 879
  in lung cancer staging, 879–880
  in pancreatic neoplasms, 875–877
  in pancreatitis, 879
  in rectal cancer, 836–839, 845, **1093–1105**
  in subepithelial lesions, 873–874
  therapeutic applications of, 882–883

Endoscopy. *See also specific techniques.*
  in gastroesophageal reflux disease, S101–S104
  in inflammatory bowel disease, **119–132**
    cholangiopancreatography in, 129–130
    colonoscopy in, 120–126
    diagnostic, 119–120
    in pouchitis, 129
    therapeutic, 127–129
    ultrasound in, 130
    upper, 126–127
  in primary sclerosing cholangitis, 331–332, 334–336

Enteral nutrition, for inflammatory bowel disease, 208–209

Enteroclysis, **717–733**
advantages of, 722
disadvantages of, 725–727
examination techniques in, 718–721
for cross-sectional imaging, 729–731
indications for, 721–725
preparation for, 718–719
previous surgery limitations in, 726–728
radiation exposure in, 726
versus computed tomography, 786

Enteropathy-associated T-cell lymphoma, in celiac disease, 630

Enteroscopy, in Crohn's disease, 127

Environmental factors
in colorectal cancer, 589
in gastric cancer, 502–504
in inflammatory bowel disease, **21–39**
appendectomy, 26
breast-feeding, 31
diet, 28–31
genetic factors interacting with, 67
hygiene, 31, 50
in pediatric patients, 276–277
nonsteroidal anti-inflammatory drugs, 32
occupation, 31–32
oral contraceptive use, 26–28
seasons, 32
socioeconomic status, 31–32
tobacco use, 21–25
in pancreatic cancer, 672–673

Epidermal growth factor receptor, in esophageal adenocarcinoma, 463

Epidermolysis bullosa acquisita, in inflammatory bowel disease, 316

Epigenetic phenomena, in carcinogenesis, 388–389
colorectal, 945–958
as early events, 949–950
as molecular markers, 953–954
gene silencing in, 946–947
genetic changes and, 950–951
types of, 1032

Episcleritis, in inflammatory bowel disease, 317

Epithelium and epithelial cells
dysplasia of. *See* Dysplasia.
gastric, *Helicobacter pylori* toxicity to, 523, 525–526
intestinal
in mucosal immunity, 84–85
leaky, in inflammatory bowel disease, 88–89
mesenchyme interactions with, 381

c-ErbB-2 protein, in esophageal adenocarcinoma, 463–464

Erythema multiforme, in inflammatory bowel disease, 316

Erythema nodosum, in inflammatory bowel disease, 315

Escherichia coli, for ulcerative colitis, 156

Esmoprazole, for GERD, intermittent therapy with, S87

Esophageal sphincter, lower. *See also* Transient lower esophageal sphincter relaxations.
control of
central mechanisms in, **S11–S20**
agents acting on, S16–S17
vagovagal, S12–S16
defects of, GERD in, S36–S39
peripheral mechanisms in, **S21–S33**

Esophagogastroduodenoscopy, in inflammatory bowel disease, 126–127

Esophagus
adenocarcinoma of, **421–440**
coding of, 421
controversy over, 481
incidence of, 441–442
global, 427–429
in United States, 422–426
trends in, 426
mortality in, 424, 426, 442–443
prognosis for, 442–443
risk factors for, 431–436, 444–456. *See also* Barrett's esophagus.
alcohol consumption, 448–449
columnar epithelial regression, 455–456
demographic, 445
dietary, 450–451
dysplasia presence, 452–453
extent of Barrett's metaplasia, 449–450
medical interventions, 453–455
medications, 452
obesity, 433, 450–451
racial, 445–446
scleroderma, 452
smoking, 447–448
socioeconomic, 446–447

Esophagus (*continued*)
symptom severity, 444–445
surveillance in, 485–490
survival rate for, 430–431, 442–443
treatment of, failure of, 443
versus adenocarcinoma of gastric cardia, 426–427
Barrett's. *See* Barrett's esophagus.
cancer of
endoscopic ultrasonography in, 880–882
histologic precursors of, 397–404
positron emission tomography in, 854–858
risk of, in gastroesophageal reflux disease, S69–S72
distention of, lower esophageal sphincter function and, S28–S31
dysplasia of
glandular, 399–404, 452–453, 488–490
squamous, 397–399
epithelium of, resistance of, to gastric acid, S40–S42
glands of, in gastric acid clearance, S39
intraepithelial neoplasia of, 398
lower sphincter relaxing medications for, adenocarcinoma risk from, 434, 452
normal cell growth and proliferation in, 381
peristalsis of, in gastric acid clearance, S39
reflux into. *See* Gastroesophageal reflux disease.
stricture of, treatment of, in pediatric patients, 917–920

Ethnic differences, in inflammatory bowel disease, 11–12, 63–64

Exercise
colorectal cancer risk and, 592
for colorectal cancer prevention, 926–927

Eye disorders, in inflammatory bowel disease, 308, 317

F

Familial adenomatous polyposis, 538–543, 1114–1119
attenuated, 539, 1115, 1117–1119
cancer prevention in, 606, 986, 1118–1119
cancer screening in, 570
clinical features of, 538–539, 1108, 1114–1115
diagnosis of, 540, 1116
epidemiology of, 538
extracolonic lesions in, 539
genetics of, 539–540, 950, 960, 962, 1108, 1115–1117
screening for, 540–541, 1117–1118
small intestinal cancer risk in, 633–634
treatment of, 541–543
variants of, 539, 1115

Familial aggregation, of inflammatory bowel disease, 64

Family history, gastric carcinogenesis and, 528

FAMMM syndrome, pancreatic cancer in, 672

Fas receptor protein, in esophageal adenocarcinoma, 466–467

Fast food, inflammatory bowel disease and, 30

Fat, dietary, as cancer cause, 375–376, 451, 594, 602

Fatty acids, inflammatory bowel disease and, 29
polyunsaturated, 211
short-chain, 156, 210–211

Fatty liver disease
nonalcoholic, hepatocellular carcinoma risk in, 649
ultrasonography in, 812

Fecal incontinence
percutaneous cecostomy for, in pediatric patients, 920–923
with inflammatory bowel disease, 350

Fecal occult blood tests, for colorectal cancer prevention, 1017–1020
cost-effectiveness of, 1071–1078

Fecal stream, qualities of, inflammatory bowel disease and, 50–51

Fiber, dietary
for colorectal cancer prevention, 575–576, 594–595, 602, 928–929, 984
for functional bowel disease, 353
inflammatory bowel disease and, 29–30

Fibroblast growth factor, in esophageal adenocarcinoma, 463

Fish oil, for inflammatory bowel disease, 211

Fistulas
in Crohn's disease, 109, 173–174, 194–195, 257–258, 260

perianal, in inflammatory bowel disease, malignant transformation of, 558–559

Flexible sigmoidoscopy. *See* Sigmoidoscopy.

Flow cytometry, in esophageal glandular dysplasia, 402

Fluorine deoxyglucose, in PET. *See* Positron emission tomography.

Fluoroscopy, for percutaneous gastrostomy or gastrojejunostomy tube placement, in pediatric patients, 909–913

Folate, for colorectal cancer prevention, 576, 599–600, 930–931, 1140–1142

Fruits, for colorectal cancer prevention, 595–596, 602, 928–929

Functional bowel disease, with inflammatory bowel disease, **347–357**
anorectal pain, 350
constipation, 350–351
definition of, 347–348
diagnosis of, 349–351
diarrhea, 351
epidemiology of, 349
fecal incontinence, 350
irritable bowel syndrome, 349–350
pathophysiology of, 351–352
treatment of, 352–355
types of, 348–349

Fundoplication. *See* Antireflux surgery.

G

Gallbladder
cancer of, ultrasonography in, 820, 823
surgery on, ultrasonography during, 830
tumors of, ultrasonography in, 820
ultrasonography of, 820–821

Gallstones
in primary sclerosing cholangitis, 338
ultrasonography in, 820

GALT (gut-associated lymphoid tissue), anatomy of, 78–79

Gamma-aminobutyric acid, lower esophageal sphincter function and, S24

Gamma-aminobutyric acid receptor agonists, lower esophageal sphincter function and, S16–S17, S114–S116

Gardner's syndrome, 1115
clinical features of, 1108
genetics of, 1108

Gas-bloat syndrome, after antireflux surgery, S100

Gastrectomy, partial, cancer in, 503–504

Gastric carcinoma. *See* Stomach, carcinoma of.

Gastric emptying, gastroesophageal reflux disease and, S38–S39

Gastric juice, reflux of. *See* Gastroesophageal reflux disease.

Gastrinoma
computed tomography in, 899–900
ultrasonography in, 828

Gastritis
atrophic, 404–406, 506
autoimmune, 505, 507
chronic, 504–509
Helicobacter pylori in, 504–509
intestinal metaplasia in, 505, 508
types of, 504–507
hemorrhage in, endovascular intervention for, 701–708
nonatrophic, 506

Gastroesophageal reflux disease
adenocarcinoma in, 432–433, 444–445
asthma and, S95–S96
atypical symptoms in, S95
Barrett's esophagus in. *See* Barrett's esophagus.
burden of illness in, S68–S69
cancer risk in, S69–S72
classification of, S1, S4–S7
current view of, **S1–S10**
new paradigm for, S4–S7
versus old paradigm, S2–S4
definition of, S2, S59, S68
epidemiology of, S60–S63
erosive, S1–S7
hereditary component of, 432–433
lower esophageal sphincter control and. *See also* Transient lower esophageal sphincter relaxations.
central mechanisms in, **S11–S20**
peripheral mechanisms in, **S21–S33**
natural history of, S3
conceptual model for, S64
nonerosive, **S59–S66**
nonerosive, S1–S4, S6–S7
definition of, S61–S62
natural history of, **S59–S66**
occult, S60–S61
pathogenesis of, **S35–S44**
acid clearance defects in, S39
antireflux defects in, S36–S39, S90

Gastroesophageal reflux disease (*continued*)
contact duration and, S36
defensive system defects in, S36–S42
offensive forces in, S36
tissue susceptibility in, S40–S42
progression of, S3
quality of life with, S68, S91
recurrence of, after antireflux surgery, S97–S98
refractory, case studies of, **S77–S84**
spectrum of, S1–S4, S60–S61
treatment of, **S67–S76, S89–S109**
based on new paradigm, S4–S7
cancer risk considerations in, S69–S72
cost-effectiveness of, S72–S74
costs of, S68–S69
endoscopic, S101–S104
esophageal adenocarcinoma risk and, 434–435
novel, **S111–S117**
persistence after, **S77–S84**
proton-pump inhibitors in. *See* Proton-pump inhibitors; *specific drugs.*
surgical, S90–S101
transient lower esophageal sphincter relaxation manipulation in, S112–S116
versus heartburn, receiver operating characteristic curves and, **S45–S58**

Gastrointestinal stromal tumor, positron emission tomography in, 863

Gastroplasty, Collis-Nissen, for GERD, S95–S96

Gastrostomy button insertion, imaging for, in pediatric patients, 915–916

Gastrostomy or gastrojejunostomy tube placement, imaging for, in pediatric patients, 909–913

Gelfoam, in endovascular embolization, for gastrointestinal hemorrhage, 703

Gender differences, in inflammatory bowel disease, 10

Gene therapy, for cancer, 390

Genetic factors
in cancer, 373–375, 384–389
colorectal, 1107–1109
gene silencing, 946–947
hereditary nonpolyposis, 960–964, 1108, 1111–1112
in Bannayan-Riley-Ruvalcaba syndrome, 1108, 1122
in Cowden syndrome, 1108, 1120–1121
in familial adenomatous polyposis, 1108, 1115–1117
in Gardner's syndrome, 1108
in hereditary mixed polyposis syndrome, 1108, 1122
in juvenile polyposis syndrome, 1108, 1120–1122
in Muir-Torre syndrome, 1108
in Peutz-Jeghers syndrome, 1108, 1125
multiple gene involvement, 951–953
pathways in, 947–949
precursor lesions and **959–970**
versus epigenetic changes, 950–951
gastric, 504, 509, 518
pancreatic, 671–673
in Crohn's disease, 310
in familial adenomatous polyposis, 950
in inflammatory bowel disease, **63–76,** 310
complexity of, 66–67
environmental factors interacting with, 67
familial aggregation in, 64
gene identification in, 67–70
in Ashkenazi Jews, 63–64
in pediatric patients, 275–276
twin studies of, 64–65
in primary sclerosing cholangitis, 330
in ulcerative colitis, 310

Genital warts, as precursor lesions, 412–413

Genitourinary disorders, in inflammatory bowel disease, 308–309, 318–319

Genome searches, of inflammatory bowel disease, 68–69

GERD. *See* Gastroesophageal reflux disease.

GETAID Crohn's disease severity index, 123–124

Glandular dysplasia, esophageal, 399–404, 452–453, 488–490. *See also* Barrett's esophagus.

Glucagonoma, computed tomography in, 897

Glucocorticoids. *See* Corticosteroids.

Glutathione, decreased, in *Helicobacter pylori* infection, 523

Glutathione-S-transferase, decreased, in *Helicobacter pylori* infection, 523

Glycogen storage diseases, hepatocellular carcinoma risk in, 649

Glycogen synthase kinase-3β, in carcinogenesis, 384–385

Goblet cells, in intestinal metaplasia, 508

Granular mucosa, in ulcerative colitis, 94

Gravity, in gastric acid clearance, S39

Growth retardation, in inflammatory bowel disease, 207

Gut-associated lymphoid tissue (GALT), anatomy of, 78–79

H

Hamartomas, in Peutz-Jeghers syndrome, 1123–1125

Hartman's pouch, creation of, for ulcerative colitis, 222–223

Heartburn. *See also* Gastroesophageal reflux disease.
  epidemiology of, S60–S63
  versus gastroesophageal reflux disease, receiver operating characteristic curves and, **S45–S58**

Heater probe therapy, for Barrett's esophagus, 491

Helicobacter hepaticus, in inflammatory bowel disease pathogenesis, 45

Helicobacter pylori infection
  gastroesophageal reflux disease and, S39
  in chronic gastritis, 504–509
  in esophageal carcinogenesis, 435–436
  in gastric carcinogenesis, 503, **517–535**
    animal models of, 521–522
    apoptosis-proliferation imbalance in, 526–527
    cancer subtypes and, 527–528
    epithelial cell toxicity in, 523, 525–526
    eradication of, 511–512, 529
    family history and, 528
    gene mutations in, 523–525
    historical view of, 517–518
    host factors in, 528
    inflammation and, 522–523
    molecular changes in, 522
    natural history and, 520–521
    transduction imbalance in, 525–526
    virulence factors and, 519–520

Hemangioma, of liver
  cavernous, ultrasonography in, 817
  computed tomography in, 766

Hematologic manifestations, of inflammatory bowel disease, 308, 317–318

Hemochromatosis, as hepatocellular carcinoma precursor, 643, 648

Hemorrhage
  gastrointestinal, endovascular intervention for, **701–715**
    angiography, 702, 708
    catheter-directed, 702–708
    embolization, 703–713
    local vasoconstrictive therapy, 709
    lower, 708–713
    upper, 701–708
    vasoconstrictive, 702–703
  in inflammatory bowel disease, endoscopic treatment of, 127–128
  in ulcerative colitis, surgery for, 220
  rectal, colonoscopic evaluation of, 575

Heparin, for ulcerative colitis, 155–156

Hepatic duct, variants of, MRCP in, 739

Hepatic vein
  obstruction of, ultrasonography in, 814–815
  sampling of, in congenital hyperinsulinism, 930–932

Hepatitis
  in inflammatory bowel disease, 53
  ultrasonography in, 811–812

Hepatitis B, as hepatocellular carcinoma precursor, 645–646

Hepatitis C, as hepatocellular carcinoma precursor, 646–647

Hepatobiliary disease, in inflammatory bowel disease, 53, 309, 321, **329–345**. *See also* Primary sclerosing cholangitis.
  abscess, 338–339
  cholangiocarcinoma, 336
  cholestasis, 338
  portal vein thrombosis, 338–339
  primary biliary cirrhosis, 338

Hepatocellular adenoma, imaging of, 773

Hepatocellular carcinoma, **641–663**
alpha-fetoprotein in, 650–651
computed tomography in, 652–653, 771–772
des-gamma-carboxyprothrombin (DCP, PIVKA-II) in, 651
epidemiology of, 641
histopathology of, 643–644
magnetic resonance imaging in, 653–654, 772
pathophysiology of, 769–771
positron emission tomography in, 861–862
predisposing conditions for, 641–649
aflatoxin exposure, 647
alpha-1-antitrypsin deficiency, 648
cirrhosis, 642–643
coexisting diseases, 647
glycogen storage diseases, 649
hemochromatosis, 643, 648
hepatitis B, 645–646
hepatitis C, 646–647
hereditary tyrosinemia, 649
metabolic diseases, 647–648
nonalcoholic fatty liver disease, 649
relative risks of, 643
Wilson disease, 648–649
screening for, 649–654
survival rate in, 641
treatment of, 641
ultrasonography in, 651–652, 818

Hepatomegaly, ultrasonography in, 811

Her-2/neu protein, in esophageal adenocarcinoma, 463–464

HER-2 protein, mice expressing, for colorectal cancer immunotherapy studies, 1004–1006

Hereditary hemochromatosis, as hepatocellular carcinoma precursor, 643, 648

Hereditary mixed polyposis syndrome
clinical features of, 1108, 1122
genetics of, 1108

Hereditary nonpolyposis colorectal cancer, 543–547, 1109–1113
clinical features of, 543, 1108–1111
diagnosis of, 544, 1111–1112
extracolonic lesions in, 539, 543, 545
genetics of, 543–546, 960–964, 1108, 1111–1112
microsatellite instability in, 545
prevention of, 986, 1113
screening for, 542, 544–545, 570–572, 1112–1113
surveillance in, 542
treatment of, 546–547
variants of, clinical features of, 1110–1111

Hereditary pancreatitis, cancer risk in, 668, 671–672

Hernia, small intestinal, computed tomography in, 793

Histamine type II receptor antagonists
esophageal adenocarcinoma risk from, 434–435
for Barrett's esophagus, 453–454
for GERD
cost-effectiveness of, S72–S73
proton-pump inhibitors with, S87–S88

Histologic precursors, of cancer, **395–430**
colorectal, 408–414
esophageal, 397–404
gastric, 404–407
small intestinal, 407–408

Histone acetylation, defects of, in carcinogenesis, 388–389

HLAs. *See* Human leukocyte antigens.

hMLH proteins. *See* MLH proteins.

hMSH proteins. *See* MSH proteins.

HNPCC. *See* Hereditary nonpolyposis colorectal cancer.

Hormone replacement therapy, colorectal cancer and, 933

Host factors, in gastric carcinogenesis, 528

hPMS proteins. *See* PMS proteins.

Human immunodeficiency virus infection
anal intraepithelial neoplasia in, 414
condyloma acuminatum in, 412–413

Human leukocyte antigens
in inflammatory bowel disease, 67–68, 310–313
in lymphocytic colitis, 301–302
in primary sclerosing cholangitis, 330

Hycosine, lower esophageal sphincter function and, S23

Hydrochloric acid, reflux of. *See* Gastroesophageal reflux disease.

Hydrocortisone, for ulcerative colitis, 152, 188

3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors in, for colorectal cancer prevention, 608–609

8-Hydroxydeoxyguanosine, in *Helicobacter pylori* infection, 523

Hygiene, inflammatory bowel disease and, 31, 50

Hyperinsulinism
colorectal cancer in, 927
congenital, diagnosis and treatment of, 926–932

Hypermethylation, of DNA, in colon cancer, **945–958**

Hyperplastic polyps, colonic, dysplasia in, 410

Hypertension
portal, ultrasonography in, 813–814
systemic, drugs for, adenocarcinoma risk from, 452

Hypnotherapy, for functional bowel disease, 355

Hypoglycemia, in congenital hyperinsulinism, diagnosis and treatment of, 926–932

I

IceA protein, as *Helicobacter pylori* virulence factor, 519

Iinflammatory bowel disease, colorectal cancer in, 100, 114, 337

Ileal pouch procedure (restorative proctocolectomy)
cancer risk with, 247–248
for ulcerative colitis, 226–232

Ileitis
backwash, in ulcerative colitis, 95, 123, 139
in Crohn's disease, treatment of, 190–191

Ileocolitis, in Crohn's disease, treatment of, 190–191

Ileorectal anastomosis, with colectomy, for ulcerative colitis, 223–224

Ileoscopy, in inflammatory bowel disease, 127

Ileostomy
for Crohn's disease, recurrence after, 51
for ulcerative colitis
Brooke, with total proctocolectomy, 224–225
continent, proctocolectomy with, 225
with subtotal colectomy, 222–223

Imaging. *See specific techniques, e.g.,* Computed tomography; Magnetic resonance imaging; Ultrasonography.

Imipramine, for functional bowel disease, 354–355

Immunodeficiency, congenital, inflammatory bowel disease and, 277–278

Immunoglobulin A, secretory, in mucosal immunity, 80

Immunology
of inflammatory bowel disease, 49–50, **77–92**
anatomy of, 78–79
cells of, 80–85
clinical relevance of, 85–86
common, 79
dendritic cells in, 83–84
extraintestinal manifestations and, 310
intestinal epithelial cells in, 84–85
intraepithelial lymphocytes in, 81
lamina propria lymphocytes in, 81–82
macrophages in, 83–84
oral tolerance in, 85
secretory immunoglobulin A in, 80
systemic versus mucosal, 77–78
T cell subsets in, 82–83
treatment based on, 86–89
of primary sclerosing cholangitis, 330–331

Immunomodulators
for Crohn's disease, 192–193
for inflammatory bowel disease, in pediatric patients, 282–287
for ulcerative colitis, 153–155

Immunosuppressive therapy, for inflammatory bowel disease, cancer risk from, 559

Immunotherapy, for colorectal cancer prevention, **1001–1013**
advantages of, 1003
animal models of, 1004–1010
immune system control and, 1002
immune system simulation in, 1003–1006
interleukin-12 in, 1009–1010

Incontinence, fecal
percutaneous cecostomy for, in pediatric patients, 920–923
with inflammatory bowel disease, 350

Indium-111, in positron emission tomography, 863, 865–866

Infections
in inflammatory bowel disease pathogenesis, 42–45, 51–52
versus inflammatory bowel disease, 120–121

Inflammation
controlled physiologic, in mucosal immunity, 82, 86
in *Helicobacter pylori* infection, 522–523

Inflammatory bowel disease
atypical, **293–305**
collagenous, 294–300
lymphocytic, 300–302
biopsy in, 122–123, 142
cancer in. *See* Cancer, in Crohn's disease; Cancer, in inflammatory bowel disease; Cancer, in ulcerative colitis.
clinical features of
in pediatric patients, 278–279
mucosal immunity and, 85–86
diagnosis of
endoscopic. *See* Endoscopy, in inflammatory bowel disease.
in pediatric patients, 279–281
differential diagnosis of
endoscopy in, 120–122
radiography in, 114–115
dysplasia in, 411–412, 1136–1137
endoscopy in. *See* Endoscopy, in inflammatory bowel disease.
environmental factors in, **21–39,** 67, 276–277
epidemiology of, **1–20,** 63
age of onset, 10–11
challenges in, 1–2
ethnic differences in, 11–12
gender distribution in, 10
incidence of, 2–10
prevalence of, 2–10
racial differences in, 11–12
temporal trends in, 2–10
exacerbations of, enteric pathogens in, 52
extent of, endoscopy in, 122–124, 126
extraintestinal manifestations of, 53, 106, **307–327**
cardiovascular, 309, 319
dermatologic, 308, 315–317, 320
epidemiology of, 307
genitourinary, 308–309, 318–319
hematologic, 308, 317–318
hepatobiliary, 53, 309, 321. *See also* Primary sclerosing cholangitis.
metastasis, 320
musculoskeletal, 206–207, 308, 311–315
neurologic, 309, 320
ophthalmologic, 308, 317
pathogenesis of, 310
pulmonary, 309, 319–320
radiography of, 106
renal, 308–309, 318–319
types of, 307–310
functional bowel disease with, **347–357**
genetic factors in, **63–76,** 275–276, 310
immunology of, 49–50, **77–92**
in pediatric patients, 207, **275–291**
in pregnancy, **265–273**
magnetic resonance imaging in, 97–99, 112, 114, 280–281
malnutrition in, 204–206
nutrition and. *See* Nutritional factors, in inflammatory bowel disease.
pathogenesis of
diet in, 203–204
extraintestinal, 310
microbial factors in, **41–62**
pathology of, **133–145**
anastomotic sites, 139–140
comparing ulcerative colitis and Crohn's disease, 133–137
in atypical presentations, 137–140
natural variation in, 138–139
nonspecific colitis diagnosis in, 140–141
pseudopolyps, 139–140
quiescent, 139
recommendations for, 142
versus serologic testing, 141–142
with coexisting diseases, 140
pouchitis in, 51, 129, 228–229
radiography of, **93–117**
for differential diagnosis, 114–115
for disease activity evaluation, 111–114
in Crohn's disease, 101–114
in ulcerative colitis, 93–101
serologic testing in, 141–142, 280
treatment of. *See also* Crohn's disease, treatment of; Ulcerative colitis, treatment of.
adhesion molecule inhibitors in, 86
antibiotics. *See* Antibiotics, for inflammatory bowel disease.

endoscopic, 127–129
immunomodulators in, 153–155, 192–193, 281–287
in bone disorders, 314–315
in cardiovascular manifestations, 319
in dermatologic manifestations, 315–317, 320
in genitourinary manifestations, 319
in hematologic abnormalities, 318
in metastatic disease, 320
in musculoskeletal manifestations, 313
in pediatric patients, 281–287
nutritional support in, 208–209
probiotics in, 55–56, 89, 156, 159, 211–212
surgical, 124–125, 172–173, 176–177, **219–235, 255–263**
tumor necrosis factor inhibitors in, 86–88
versus congenital immunodeficiency, 277–278

Infliximab
for Crohn's disease, 87, 171, 174–176
intestinal, 190
maintenance, 191
perineal, 194
for inflammatory bowel disease, 270–271, 287

Injection therapy, endoscopic, for GERD, S103

Insulin-like growth factor, excess of, colorectal cancer in, 927

Insulin resistance, colorectal cancer in, 926–927

Insulinoma
computed tomography in, 897–899
ultrasonography in, 828

Integrins, release of, from intraepithelial lymphocytes, 81

Interleukin(s)
imbalance of, in inflammatory bowel disease, 87–88
in *Helicobacter pylori* infection, 521, 526
in mucosal immunity, 82–85

Interleukin-12, for immunotherapy, in colorectal cancer, 1009–1010

Intestinal epithelial cells
in mucosal immunity, 84–85
leaky, in inflammatory bowel disease, 88–89

Intestinal metaplasia
at gastroesophageal junction, 426–427, 431–432
in Barrett's esophagus, 399, 461
in gastritis, 405–406, 505, 508

Intestine. *See also* Colon; Small intestine.
fecal stream qualities in, inflammatory bowel disease and, 50–51
hemorrhage of, endovascular intervention for, 708–713
mucosal barrier defects in, in inflammatory bowel disease, 46, 48–49

Intraductal papillary mucinous tumors, of pancreas, computed tomography in, 903–905

Intraepithelial lymphocytes, in mucosal immunity, 81

Intraepithelial neoplasia
anal, 413–414
esophageal, 398

Intubation, in enteroclysis, 719–721, 725

Irritable bowel syndrome, with inflammatory bowel disease, 349–350

J

Jejunostomy button, insertion of, imaging for, in pediatric patients, 915–916

Jejunostomy tube, insertion of, imaging for, in pediatric patients, 914–915

Juvenile polyposis syndrome, 1119–1123
cancer prevention in, 1123
cancer screening in, 1122–1123
clinical features of, 1108, 1119–1120
colonic, 410
diagnosis of, 1122
genetics of, 1108, 1120, 1122
small intestinal, 408
variants of, 1120–1122

K

Ki-67 antigen, in esophageal adenocarcinoma, 462

Kidney dysfunction, in inflammatory bowel disease, 308–309, 318–319

Kock pouch, for ulcerative colitis, 225

L

Lactobacilli, for inflammatory bowel disease, 55, 211–212

Lactose intolerance, in inflammatory bowel disease, 353

Lamina propria, lymphocytes of, in mucosal immunity, 81–82

Lansoprazole, for Barrett's esophagus, 483

Laparoscopic surgery, in Crohn's disease, 259–260

Laryngeal stimulation, lower esophageal sphincter function and, S27, S31

Laser therapy, for Barrett's esophagus, 491–493

Left-handedness, as inflammatory bowel disease risk factor, 33

Leukocyte adhesion deficiency, inflammatory bowel disease and, 277–278

Leukotrienes, in *Helicobacter pylori* infection, 521

Levator ani syndrome, with inflammatory bowel disease, 350

Lidocaine, for Crohn's disease, 189

Linkage analysis, of inflammatory bowel disease genes, 68–69

Listeria monocytogenes, in inflammatory bowel disease pathogenesis, 44–45

Liver
- abscess of
  - in inflammatory bowel disease, 338–339
  - ultrasonography in, 816
- adenoma of, ultrasonography in, 817
- biopsy of
  - in primary sclerosing cholangitis, 332
  - percutaneous, imaging for, in pediatric patients, 923–925
- cancer of, **761–778**. *See also* Hepatocellular carcinoma.
  - computed tomography in
    - cholangiocarcinoma, 774
    - hepatocellular carcinoma, 771
    - lymphoma, 775
    - metastatic, 764–766
    - principles of, 761–762
    - versus hepatocellular adenoma, 773
  - magnetic resonance imaging in
    - cholangiocarcinoma, 774
    - fibrolamellar carcinoma, 772
    - hepatocellular carcinoma, 772
    - lymphoma, 776
    - metastatic, 767–768
    - principles of, 762–764
    - versus hepatocellular adenoma, 773
  - positron emission tomography in, 861–862
  - ultrasonography in, 818–819
- cavernous hemangioma of, ultrasonography in, 817
- chloroma of, ultrasonography in, 818
- cholangiocarcinoma of, imaging of, 773–774
- cirrhosis of, ultrasonography in, 812–813
- cystic disease of, ultrasonography in, 815–816
- diffuse disease of, ultrasonography in, 811–815
- disorders of, in inflammatory bowel disease, 53. *See also* Hepatobiliary disease, in inflammatory bowel disease; Primary sclerosing cholangitis.
- fatty, ultrasonography in, 812
- fibrolamellar carcinoma of, 772
- focal nodular hyperplasia of, ultrasonography in, 817
- hemangioma of, computed tomography in, 766
- lymphoma of
  - computed tomography in, 775
  - magnetic resonance imaging in, 776
  - ultrasonography in, 818
- metastasis to
  - computed tomography in, 764–766
  - magnetic resonance imaging in, 767–768
  - ultrasonography in, 818
- nodules of, versus hepatocellular carcinoma, 771–772
- normal cell growth and proliferation in, 383
- regeneration of, 383
- surgery on, ultrasonography during, 830
- transplantation of
  - in primary sclerosing cholangitis, 334
  - ultrasonography in, 819–820
- tumors of, ultrasonography in, 817–819

ultrasonography of, 811–820

Lkb1 (STK11) gene and product, mutations of
in colorectal cancer, 952
in Peutz-Jeghers syndrome, 634, 1125

Loperamide
for functional bowel disease, 353–354
lower esophageal sphincter function and, S25

Lorazepam, for enteroclysis, 719

Lovastatin, for colorectal cancer prevention, 609

Loxiglumide, lower esophageal sphincter function and, S24

Lung
cancer of, staging of, endoscopic ultrasonography in, 879–880
disorders of, in inflammatory bowel disease, 309, 319–320

Lymphocytes. *See also* T lymphocytes.
lamina propria, in mucosal immunity, 81–82

Lymphocytic colitis, 300–302

Lymphoma
in inflammatory bowel disease, 559, 632
of liver
computed tomography in, 775
magnetic resonance imaging in, 776
ultrasonography in, 818
of pancreas, endoscopic ultrasonography in, 877
of small intestine
in celiac disease, 629–631
in Crohn's disease, 632
positron emission tomography in, 862, 865

Lynch syndrome. *See* Hereditary nonpolyposis colorectal cancer.

M

M cells, function of, 79, 85

Macrophages, in mucosal immunity, 81–84

MADH5 (SMAD4) gene, mutations of, in juvenile polyposis syndrome, 1120, 1122

Magnetic resonance cholangiography, in primary sclerosing cholangitis, 332

Magnetic resonance cholangiopancreatography, **735–750**
in biliary disorders
choledocholithiasis, 739, 741–743
congenital variants and anomalies, 737–739
injuries, 743
obstruction, 739–740
strictures, 739–740
in choledocholithiasis, 878–879
in pancreatic disorders, 743–747
acute pancreatitis, 745
chronic pancreatitis, 745–746
congenital anomalies, 744
injuries, 744–745
neoplasms, 746–747
in pediatric patients, 907–909
patient preparation for, 737
technical aspects of, 736–737

Magnetic resonance imaging
in colorectal cancer screening, 579
cost-effectiveness of, 1082–1084
versus computed tomography colonography, 1057
in Crohn's disease, 112, 114, 280–281
in enteroclysis, 729–731
in hepatocellular carcinoma, 653–654
in liver cancer. *See* Liver, cancer of, magnetic resonance imaging in.
in pediatric patients, 908
in rectal cancer staging, 840–845
in ulcerative colitis, 97–99, 280–281
in virtual colonoscopy. *See* Virtual colonoscopy.

Mallory-Weiss tears, endovascular intervention for, 701–708

Malnutrition, in inflammatory bowel disease, 204–206

MALT (mucosa-associated lymphoid tissue), anatomy of, 78–79

Measles virus, in inflammatory bowel disease pathogenesis, 44

Mechanoreceptors, in lower esophageal sphincter control, S12, S15

Medulloblastoma, in Turcot syndrome, 1115

Megacolon, toxic, in ulcerative colitis, 99, 188, 220

Melanoma, positron emission tomography in, 863

6-Mercaptopurine
for Crohn's disease, 170–171, 173, 175–177
gastroduodenal, 189
intestinal, 190–191
perineal, 194–195

6-Mercaptopurine (*continued*)
steroid-refractory, 192
for inflammatory bowel disease
in pediatric patients, 283–285
in pregnancy, 269–270
monitoring of, 284–285
safety of, 285
for ulcerative colitis, 153
in pancolitis, 187
steroid-refractory, 188–189

Mesalamine
for Crohn's disease, 168–169, 174, 302
gastroduodenal, 189
intestinal, 190
recurrent, 195
for inflammatory bowel disease, in pregnancy, 269
for ulcerative colitis, 148–150
distal, 186
in proctitis, 186

Mesalazine, for ulcerative colitis, 187

Mesenchyme, epithelium interactions with, 381

Mesentery, fibrofatty proliferation of, in Crohn's disease, 108

Metastasis
detection of, mutational analysis in, 390
from colon
molecular markers for, 954
positron emission tomography in, 854
from Crohn's disease, 320
from pancreas, positron emission tomography in, 859–860
to liver
computed tomography in, 764–766
magnetic resonance imaging in, 767–768
ultrasonography in, 818

Methotrexate
for Crohn's disease, 171, 173, 175, 192
for inflammatory bowel disease
in pediatric patients, 285–286
in pregnancy, 270
for ulcerative colitis, 153–154

Methscopolamine, lower esophageal sphincter function and, S23–S24

Methylation, DNA. *See* DNA, hypermethylation of.

Methylcellulose, for enteroclysis, 719

5-Methylcytosine, mutagenic properties of, 946

Methylprednisolone, for ulcerative colitis, 151–152, 188

Metronidazole
for collagenous colitis, 299
for Crohn's disease, 168, 173, 176
in peritonitis, 191
intestinal, 190
perineal, 194
recurrent, 195
for inflammatory bowel disease, 53–54, 269
for ulcerative colitis, 152

MGMT gene, mutations of, in colorectal cancer, 949–954

Microbial factors, in inflammatory bowel disease, **41–62**
aberrant immune response, 49–50
dysbiosis, 45–47
infections, 42–45, 51–52
luminal contents and, 49–51
mucosal barrier defects, 46, 48–49
theories of, 42–50
treatment related to, 53–56

Microsatellite instability
in colorectal cancer, 948, 950, 962
in esophageal adenocarcinoma, 470

Microscopic colitis, in inflammatory bowel disease, 312–313

Minicamera, for endoscopy, small bowel, 127

Mismatch repair, defects of, in carcinogenesis, 387–388, 470
colorectal, 543–546, 950
gastric, 524–525

MLH proteins
defects of
in colorectal cancer, 543–545, 948–954, 994, 1111–1112
in gastric cancer, 387–388
in pancreatic cancer, 672
in mismatch repair system, 387–388, 960–964, 1111

MMAC gene, mutations of, in juvenile polyposis syndrome, 1120–1122

MMR genes, mutations of, in hereditary nonpolyposis colorectal cancer, 543–546

Morphine, lower esophageal sphincter function and, S24–S25, S114

Mortality
in colonoscopy, 1040
in esophageal adenocarcinoma, 424, 426

Mouth lesions
in Crohn's disease, treatment of, 189
in inflammatory bowel disease, 316

MRCP. *See* Magnetic resonance cholangiopancreatography.

MSH proteins
defects of
in colorectal cancer, 543–545, 948, 950–951, 962, 1112
in gastric cancer, 387–388
in pancreatic cancer, 672
in inflammatory bowel disease, 554–555
in mismatch repair system, 962, 1112

MUC2 gene, mutations of, in esophageal adenocarcinoma, 471

Mucosa-associated lymphoid tissue (MALT), anatomy of, 78–79

Mucosal barrier, intestinal, defects of, in inflammatory bowel disease, 46, 48–49

Mucosal immunity, in inflammatory bowel disease, **77–92**
anatomy of, 78–79
cells of, 80–85
clinical relevance of, 85–86
oral tolerance in, 85
secretory immunoglobulin A in, 80
treatment based on, 86–89
versus systemic immunity, 77–78

Mucosal resection, endoscopic, for Barrett's esophagus, 493–494

Mucus, gastric, *Helicobacter pylori* degradation of, 523

Muir-Torre syndrome
clinical features of, 1108, 1110
genetics of, 1108

Multiple endocrine neoplasia syndrome, gastric dysplasia in, 406–407

Multipolar electrocoagulation, for Barrett's esophagus, 491

Musculoskeletal disorders, in inflammatory bowel disease, 206–207, 308, 311–315

c-*myb* gene and product, mutations of, in esophageal adenocarcinoma, 472

c-*myc* gene and product, mutations of, in esophageal adenocarcinoma, 469

Mycobacterium paratuberculosis, in inflammatory bowel disease pathogenesis, 43–44

Mycophenolate mofetil, for Crohn's disease, 192–193

N

Neoplasms. *See* Tumor(s).

Nephrolithiasis, in inflammatory bowel disease, 318–319

Neuroendocrine cell dysplasia, gastric, 406–407

Neuroendocrine tumors, of pancreas, computed tomography in, 897–901

Neurologic disorders, in inflammatory bowel disease, 309, 320

Neutrophilic dermatosis, acute febrile (Sweet's syndrome), in inflammatory bowel disease, 316

Nicotine, inflammatory bowel disease and, 25, 155

Nissen fundoplication, for GERD, S96

Nitric oxide, lower esophageal sphincter function and, S24, S114

NOD2 gene and product, variants of, in Crohn's disease, 69–70, 89

Nonalcoholic fatty liver disease, hepatocellular carcinoma risk in, 649

Nonerosive gastroesophageal reflux disease. *See* Gastroesophageal reflux disease, nonerosive.

Nonsteroidal anti-inflammatory drugs. *See also specific drugs.*
for arthropathy, in inflammatory bowel disease, 313
for colorectal cancer prevention, 577–578, 604–607, 932–933, 1139–1141
inflammatory bowel disease and, 32

Nuclear factor-κB, in *Helicobacter pylori* infection, 526

Nutritional factors. *See also* Diet.
in inflammatory bowel disease, 28–31, **203–218**
enteral feeding in, 208–209
for management, 207–212
growth and development retardation and, 207
inadequate (malnutrition), 204–206
osteopenia development and, 206–207
parenteral, 172, 210
pathogenesis of, 203–204

Nutritional factors (*continued*)
perioperative, 210
pharmacology of, 210–212

O

Obesity
Barrett's esophagus in, 450–451
colorectal cancer in, 926–927
esophageal adenocarcinoma in, 433, 450–451

Obstructive uropathy, in inflammatory bowel disease, 319

Obturator hernia, computed tomography in, 793

Occupation, inflammatory bowel disease and, 31–32

Ocular complications, of inflammatory bowel disease, 308, 317

Olsalazine, for ulcerative colitis, 148–149

Omeprazole
for Barrett's esophagus, 454, 482–483
for GERD
cost-effectiveness of, S72–S73
intermittent therapy with, S86–S87
versus surgical therapy, S92, S94

Ophthalmologic manifestations, of inflammatory bowel disease, 308, 317

Oral contraceptives, inflammatory bowel disease and, 26–28

Oral tolerance, immunology of, 85

Osteochondritis dissecans, in inflammatory bowel disease, 314–315

Osteomalacia, in inflammatory bowel disease, 314

Osteonecrosis, in inflammatory bowel disease, 314–315

Osteopenia, in inflammatory bowel disease, 206–207, 313–315

Osteoporosis, in inflammatory bowel disease, 313–315

Oxygen free radicals, in gastric carcinogenesis, 522–523

P

p14 gene and product, mutations of, in colorectal cancer, 948, 952–953

p16 gene and product, mutations of
in colorectal cancer, 947–949, 952–953
in esophageal adenocarcinoma, 462–463
in inflammatory bowel disease, 554–556
in pancreatic cancer, 669–670, 672

p27 gene and product, mutations of, in inflammatory bowel disease, 554, 556

p53 gene and product, mutations of
in carcinogenesis, 387
in esophageal adenocarcinoma, 467–468
in esophageal glandular dysplasia, 403–404
in gastric carcinoma, 508
in inflammatory bowel disease, 553–555
in pancreatic cancer, 669

Pain, anorectal, functional, with inflammatory bowel disease, 350

Pancolitis, in ulcerative colitis, 94, 187

Pancreas
adenoma of, computed tomography in, 901
cancer of, **665–680**
carcinogenesis pathways for, 668–671
cystic fibrosis as risk factor for, 666–667
endoscopic ultrasonography in, 875–877
karyotype analysis of, 669–670
localized treatment of, 883
pancreatitis as risk factor for
carcinogenesis pathways in, 670–671
evidence for, 666–668
gene–environment interactions in, 672–673
gene–gene interactions in, 671–672
hereditary, 668, 671–672
tropical, 667–668
positron emission tomography in, 858–861
risk reduction for, 673–674
screening for, 674–675
ultrasonography in, 826–828, 883
congenital anomalies of, MRCP in, 744
cysts of
computed tomography in, 901–905
endoscopic ultrasonography in, 877
ultrasonography in, 826–828
inflammation of. *See* Pancreatitis.

injuries of, MRCP in, 744–745
intraductal papillary mucinous tumors of, computed tomography in, 903–905
lymphoma of, endoscopic ultrasonography in, 877
magnetic resonance imaging of. *See* Magnetic resonance cholangiopancreatography.
mucinous cystic neoplasms of, computed tomography in, 901–902
normal cell growth and proliferation in, 383
pseudocysts of
computed tomography in, 901
drainage of, endoscopic ultrasonography in, 882
ultrasonography in, 826
tumors of. *See also* Pancreas, cancer of.
MRCP in, 746–747
ultrasonography in, 826–828
ultrasonography of, 824–828

Pancreas divisum, MRCP in, 744

Pancreatic duct
adenocarcinoma of
computed tomography in, 892–897
ultrasonography in, 826
injury of, MRCP in, 744–745
papillary mucinous tumors of, computed tomography in, 903–905

Pancreatic vein, transhepatic sampling of, in congenital hyperinsulinism, 928–930

Pancreatitis
acute
MRCP in, 745
ultrasonography in, 825–826
cancer risk in. *See* Pancreas, cancer of, pancreatitis as risk factor for.
chronic
MRCP in, 745–746
ultrasonography in, 826, 879

Pangastritis, *Helicobacter pylori* in, 504–505

Parenteral nutrition
for Crohn's disease, 172
for inflammatory bowel disease, 210

Parietal cells, autoimmune destruction of, 505

Pediatric patients
imaging in, **907–934**
for congenital hyperinsulinism, 926–932
for esophageal stricture treatment, 917–920
for gastrostomy button insertion, 915–916
for hepatic vein sampling, 930–932
for jejunal tube insertion, 914–915
for percutaneous cecostomy, 920–923
for percutaneous gastrostomy or gastrojejunostomy tube placement, 909–913
for percutaneous liver biopsy, 923–925
for transhepatic pancreatic vein sampling, 928–930
techniques for, 907–909
inflammatory bowel disease in, **275–291**
clinical features of, 278–279
diagnosis of, 279–281
environmental factors in, 276–277
genetic factors in, 275–276
growth retardation in, 207
treatment of, 282–287
versus congenital immunodeficiency, 277–278

Pepsin, reflux of. *See* Gastroesophageal reflux disease.

Peptic ulcer disease, hemorrhage in, endovascular intervention for, 701–708

Percutaneous procedures, imaging for
cecostomy, 920–923
gastrostomy or gastrojejunostomy tube placement, 909–913
hepatic vein sampling, 930–932
liver biopsy, 923–925
transhepatic cholangiography, 907–909
transhepatic pancreatic vein sampling, 928–930

Perianal fistulas, in inflammatory bowel disease, malignant transformation of, 558–559

Perineum, Crohn's disease of, 194–195, 261–260

Peripheral arthropathy, in inflammatory bowel disease, 311–313

Peristalsis, esophageal, in gastric acid clearance, S39

Peritonitis, in Crohn's disease, 191

PET. *See* Positron emission tomography.

Peutz-Jeghers syndrome, 1123–1126
cancer prevention in, 1126
cancer screening in, 1125–1126
clinical features of, 1108, 1123–1125
diagnosis of, 1125
genetics of, 1108, 1125
pancreatic cancer in, 672
small intestinal cancer in, 634
small intestinal polyps in, 408

Peyer's patches, function of, 79

Pharyngeal stimulation, lower esophageal sphincter function and, S25–S26, S31

Photodynamic therapy, for Barrett's esophagus, 492–493

Physical activity, colorectal cancer risk and, 592

Pigmentation disorders, in Peutz-Jeghers syndrome, 1123–1124

Piroxicam, for colorectal cancer prevention, 607

PIVKA-II (DCP, des-gamma-carboxyprothrombin), in hepatocellular carcinoma, 651

Pleuropericarditis, in inflammatory bowel disease, 319

Ploidy, DNA, in esophageal adenocarcinoma, 469–470

PMS proteins
in mismatch repair system, 387–388
mutations of
in colorectal cancer, 543–545
in gastric cancer, 525

Polymerase chain reaction, in cancer management, 389–390

Polymethyl methacrylic acid, endoscopic injection of, for GERD, S103

Polyp(s)
colonic. *See* Colon, polyps of; Familial adenomatous polyposis.
gallbladder, ultrasonography in, 820
gastric, 404–406, 1114
postinflammatory, in Crohn's disease, 103
small intestinal, 633–634, 1114

Polypectomy, colonic, 566–567, 1137–1138

Portal hypertension, ultrasonography in, 813–814

Portal vein thrombosis
in inflammatory bowel disease, 338–339
ultrasonography in, 814

Portosystemic shunt, ultrasonography of, 814

Positron emission tomography, **849–869**
in colorectal cancer, 850–854
in esophageal cancer, 854–858
in liver disorders, 861–862
in lymphoma, 862, 865
in melanoma, 863
in pancreatic carcinoma, 858–861
in splenic disorders, 862
in stomach disorders, 863
principles of, 849
radiolabeled antibodies in, 863–865
radiolabeled peptides in, 865–866

Postganglionic neurons, in lower esophageal sphincter control, S13

Posture, lower esophageal sphincter function and, S22

Pouchitis
after proctocolectomy, 228–229
endoscopy in, 51, 129

Prebiotics, for inflammatory bowel disease, 55

Prednisolone
for inflammatory bowel disease, 269
for ulcerative colitis, 152

Prednisone
for collagenous colitis, 299
for Crohn's disease, 170, 173, 190
for inflammatory bowel disease, 269
for ulcerative colitis, 151, 186–187

Preganglionic neurons, in lower esophageal sphincter control, S13–S15

Pregnancy, inflammatory bowel disease in, **265–273**
diagnosis during, 267–268
disease effects on pregnancy, 266–267
fertility rate and, 265–266
pregnancy effects on, 267
surgery during, 267–268
treatment of, 268–271

Premalignant disorders
atrophic gastritis, 404–406, **499–516**
Barrett's esophagus. *See* Barrett's esophagus.
carcinogenesis mechanisms and. *See* Carcinogenesis.
celiac disease, **625–639**
colorectal cancer development from. *See* Colorectal cancer.
early detection of, **369–378**
Helicobacter pylori in. *See*

Helicobacter pylori infection.
hepatocellular carcinoma development from, **641–663**
histologic precursors in, **395–420**
inflammatory bowel disease, 411–412, **551–564**
pancreatitis, **665–680**

Primary biliary cirrhosis, in inflammatory bowel disease, 338

Primary sclerosing cholangitis
cigarette smoking and, 24
in inflammatory bowel disease, 101, 129–130, 241–242, 329–338, 559
cholangiocarcinoma in, 336–337
cholestasis in, 338
clinical features of, 332–333
colorectal cancer in, 337
complications of, 337–338
diagnosis of, 331–332
epidemiology of, 329–330
laboratory features of, 333
natural history of, 332–333
pathogenesis of, 330–331
treatment of, 333–336

Probiotics
for inflammatory bowel disease, 55–56, 89, 211–212
for ulcerative colitis, 156, 159

Proctalgia, with inflammatory bowel disease, 350

Proctitis, in ulcerative colitis, 185–186

Proctocolectomy, for ulcerative colitis
restorative, 226–232, 247–248
total, with Brooke ileostomy, 224–225
with continent ileostomy, 225

Proliferative cell nuclear antigen (PCNA), in esophageal adenocarcinoma, 462

Proton-pump inhibitors. *See also specific drugs.*
for Barrett's esophagus, 483–484
for GERD
cost-effectiveness of, S72–S74
failure of, case studies of, **S77–S84**
histamine-2 receptor antagonists with, S87–S88
intermittent therapy with, S86–S87
novel methods using, **S85–S88**
on-demand therapy with, S86–S87

Pseudo-Billroth I sign, in Crohn's disease, 103

Pseudocysts, pancreatic
computed tomography in, 901
drainage of, 882
ultrasonography in, 826, 882

Pseudopolyps
in Crohn's disease, 103
in ulcerative colitis, 139–140

Psoriasis, in inflammatory bowel disease, 316

Psychotherapy, for functional bowel disease, 355

PTEN gene, mutations of, in juvenile polyposis syndrome, 1120–1122

Pulmonary disorders, in inflammatory bowel disease, 309, 319–320

Pyoderma gangrenosum, in inflammatory bowel disease, 315–316

Pyostomatitis vegetans, in inflammatory bowel disease, 316

R

Racial factors
in Barrett's esophagus, 445–446
in inflammatory bowel disease, 11–12

Radiation therapy, for rectal cancer, staging after, 845

Radiofrequency therapy, endoscopic, for GERD, S102–S103

Radiography, of inflammatory bowel disease. *See* Inflammatory bowel disease, radiography of.

Ram's horn sign, postinflammatory, 103

Ranitidine
for Barrett's esophagus, 482
for GERD, cost-effectiveness of, S72–S73

ras genes and products, mutations of
in carcinogenesis, 385–386
in colorectal cancer, 579
in esophageal adenocarcinoma, 468–469
in inflammatory bowel disease, 554–555
in pancreatic cancer, 669–

Reactive atypia, versus dysplasia, 396, 398

Reactive oxygen species, in gastric carcinogenesis, 522–523

Receiver operating characteristic curves, for heartburn versus gastroesophageal reflux disease studies, **S45–S58**

Rectal cancer
biopsy in, 1098–1099
endoscopic ultrasonography of, **1093–1105**
impact on management, 1097–1099
in recurrent disease, 1100–1101
learning procedure for, 1099–1100
results of, 1094–1097
technique for, 1094
staging of, **835–847**
after chemoradiotherapy, 845
endosonography in, 836–839, 845, **1093–1105**
magnetic resonance imaging in, 840–845

Rectum, inflammatory disease of, 122
appearance of, 97
pain in, 350

Reflex(es), vagovagal, in lower esophageal sphincter control, S12–S16

Reflux, gastroesophageal. *See* Gastroesophageal reflux disease.

Refractory sprue, lymphoma in, 631

Rendition, for GERD, intermittent therapy with, S86

Restorative proctocolectomy, for ulcerative colitis, 226–232, 247–248

Retinal pigment, congenital hypertrophy of, in familial adenomatous polyposis, 1114

Retinoblastoma gene, in esophageal adenocarcinoma, 464

Retinoic acid receptors, in esophageal adenocarcinoma, 472

Rheumatic disease, in inflammatory bowel disease, 311–313

Richter's hernia, computed tomography in, 793

S

Saccharomyces cerevisiae, autoantibodies to, in inflammatory bowel disease, 141–142

Sacroiliitis, in inflammatory bowel disease, 313

Salivary glands, in gastric acid clearance, S39

Sanitation, inflammatory bowel disease and, 31, 50

Santorinicele, MRCP in, 744

Scleroderma, esophageal metaplasia and adenocarcinoma in, 452

Sclerosing cholangitis. *See also* Primary sclerosing cholangitis.
MRCP in, 740

Screening
for Barrett's esophagus, 372
for cancer. *See* Cancer, screening and surveillance for; Colorectal cancer, screening and surveillance for.
for familial adenomatous polyposis, 540–541

Seasonal variations, in inflammatory bowel disease, 32

Secretory immunoglobulin A, in mucosal immunity, 80

Sedation, for enteroclysis, 719

Selenium, for colorectal cancer prevention, 598, 603–604, 930

Sepsis, in proctocolectomy, 228

Sigmoidoscopy, for colorectal cancer prevention, **1015–1029**
colonoscopy after, 1039
controversy over, 1025–1026
cost-effectiveness of, 1023–1024, 1077, 1082
evidence supporting, 1016–1019
fecal occult blood tests with, 1017–1020
future of, 1026
implementation of, 1020
intervals between, 1026
nonphysician examiners for, 1020
positive results in, 1025, 1039
risks of, 1024
technical competence in, 1025–1026
versus colonoscopy, 1021–1025

Sinus tracts, in Crohn's disease, 109

Skin disorders, in inflammatory bowel disease, 308, 315–317, 320

SMAD gene and proteins, mutations of
in carcinogenesis, 386–387
in juvenile polyposis syndrome, 1120, 1122

Small intestine
adenocarcinoma of, 408
adenomas of, 407–408
cancer of, **625–639**
epidemiology of, 625–626
histologic precursors of, 407–408

predisposing conditions for, 626–634
celiac disease, 627–631
Crohn's disease, 631–632
familial adenomatous polyposis, 633–634
Peutz-Jeghers syndrome, 634
prognosis for, 626
dysplasia of, 407–408
endoscopy of, in inflammatory bowel disease, 127
hemorrhage of, endovascular intervention for, 708–713
ischemia of, in strangulation, 786–791
normal cell growth and proliferation in, 381–382
obstruction of
computed tomography in, 782–794
adhesive, 791–793
closed-loop, 786
complete, 782–784
for etiology determination, 791–798
in Crohn's disease, 794–795
in hernia, 793
neoplastic, 793–794
partial, 784–786
postoperative, 795, 797–798
recurrent, 785–786
strangulation, 786–791
technique for, 781–782
versus enteroclysis, 786
versus plain film radiography, 779–781
in Crohn's disease, 191
polyps of, in familial adenomatous polyposis, 633–634, 1114
radiologic examination of. *See* Enteroclysis.

Smoking
disease risk in
Barrett's esophagus, 447–448
colorectal cancer, 601, 931–932
esophageal adenocarcinoma, 433–434, 447–448
gastric cancer, 502–503
inflammatory bowel disease, 21–25
pancreatic cancer, 672–673
primary sclerosing cholangitis, 24

Smooth muscle relaxants, for functional bowel disease, 354

Snuff use, inflammatory bowel disease and, 24–25

Socioeconomic factors
in Barrett's esophagus, 446–447
in inflammatory bowel disease, 31–32

Somatostatinoma, computed tomography in, 897

Spasmolytic agents, for virtual colonoscopy, 1047

Specialized intestinal metaplasia, in Barrett's esophagus, 399

Spinal cord, in lower esophageal sphincter control, S12–S16

Spine, inflammatory bowel disease manifestations in, 312–315

SPINK1 gene and product, mutations of, pancreatic cancer in, 667

Spleen, positron emission tomography of, 862

Spondyloarthopathy, in inflammatory bowel disease, 312–313

Sprue, refractory, lymphoma in, 631

Squamous cell dysplasia, esophageal, 397–399

Staging
of colorectal cancer, 874–875
of lung cancer, 879–880
of rectal cancer, **835–847, 1093–1105**

Starches, dietary, colorectal cancer risk and, 593–594

Statins, for colorectal cancer prevention, 608–609

STK11 (Lkb1) gene and product, mutations of
in colorectal cancer, 952
in Peutz-Jeghers syndrome, 634, 1125

Stomach
adenocarcinoma of
adenoma transformation into, 406
versus esophageal adenocarcinoma, 426–427
adenomas of, 405–406
cancer of
endoscopic ultrasonography in, 879
histologic precursors of, 404–407
positron emission tomography in, 863
carcinoma of, **499–516**
adenoma transformation into, 406
anatomic locations of, 502

Stomach (*continued*)
apoptosis-proliferation imbalance in, 526–527
chronic gastritis and, 504–509
diffuse type of, 500–501, 527–528
epidemiology of, 499–504, 517–518
family history and, 528
genetics of, 518, 523–525
host factors in, 528
intestinal type of, 500–501, 527–528
prevention of, 529
risk factors for, 502–504. *See also Helicobacter pylori* infection.
screening for, 510
surveillance in, 510–512
types of, 500–502, 527–528
Crohn's disease of, 103, 105
endoscopy in, 126
treatment of, 189
distention of, lower esophageal sphincter function and, S23
dysplasia of
endocrine cell, 406–407
epithelial, 404–406
normal cell growth and proliferation in, 381–382
polyps of, 404–406
in familial adenomatous polyposis, 1114

Stomatitis, in inflammatory bowel disease, 316

Stones
biliary tract
MRCP in, 741–742, 749
ultrasonography in, 822
gallbladder, ultrasonography in, 820
kidney, in inflammatory bowel disease, 318–319

Stool genetic testing, in colorectal cancer, 579

Strangulation, of small intestine, computed tomography in, 786–791

Streptococcus thermophilus, for inflammatory bowel disease, 55, 159

Strictures, in Crohn's disease, 103–104, 261

String sign, in Crohn's disease, 103

Sucrase-isomaltase, in esophageal adenocarcinoma, 471

Sugars, dietary
colorectal cancer risk and, 593–594
inflammatory bowel disease and, 28–29

Sulfapyridine, for ulcerative colitis, 54

Sulfasalazine
for collagenous colitis, 299
for colorectal cancer prevention, 1139–1140
for Crohn's disease, 168, 174, 176, 190
for inflammatory bowel disease, in pregnancy, 269
for ulcerative colitis, 54, 147–150, 187

Sulindac, for colorectal cancer prevention, 577–578, 604, 606–607, 986

Surveillance
in Barrett's esophagus, 485–490
in cancer, 369–373
colorectal. *See* Colorectal cancer, screening and survillance for.
esophageal, 485–490
gastric, 510–512
in familial adenomatous polyposis, 540–541
in inflammatory bowel disease, 559–560, 573–574

Suturing, endoscopic, for GERD, S101–S102

Sweet's syndrome, in inflammatory bowel disease, 316

Synbiotics, for inflammatory bowel disease, 55

T

T lymphocytes
in lymphoma, in celiac disease, 630–631
in mucosal immunity
antigen-presenting cell recognition by, 83–84
inflammatory subsets of, 82–83
intraepithelial, 81
lamina propria, 81–82
regulatory subsets of, 82–83

Tacrolimus, for Crohn's disease, 195

Target sign
in Crohn's disease, 107
in ulcerative colitis, 96–97

Telomerase, in esophageal adenocarcinoma, 472

Tetrahydrocannabinol, action of, on lower esophageal sphincter, S17

Thalidomide, for Crohn's disease, 189, 193–194

Theophylline, esophageal adenocarcinoma risk from, 434

Thrombocytopenia, in inflammatory bowel disease, 318

Thromboembolism, in inflammatory bowel disease, 318

Thrombosis, portal vein
in inflammatory bowel disease, 338–339
ultrasonography in, 814

Tobacco use. *See* Smoking.

Tolerance, oral, immunology of, 85

Toothpaste, inflammatory bowel disease and, 30–31

Total body computed tomography scanning, colonography in, 1058

Toupet fundoplication, for GERD, S96

Toxic megacolon, in ulcerative colitis, 99–100, 188, 220

Transduction pathways, *Helicobacter pylori* effects on, 525–526

Transforming growth factor-α, in esophageal adenocarcinoma, 463

Transforming growth factor-β
in carcinogenesis, 386–387
in inflammatory bowel disease, 554–555
in mucosal immunity, 83

Transient lower esophageal sphincter relaxations, control of
central mechanisms in, S11–S12
peripheral mechanisms in, S22–S31
physiology of, S37–S38, S112
treatment based on, S112–S116

Transjugular liver biopsy, in pediatric patients, 924–925

Transplantation, liver
in primary sclerosing cholangitis, 334
ultrasonography in, 819–820

Tropical pancreatitis, cancer risk in, 667–668

Tubular adenomas, colonic, 409

Tubulovillous adenomas, colonic, 409

Tumor(s). *See also* Cancer.
of biliary tract, MRCP in, 739–740
of gallbladder, ultrasonography in, 820
of liver, ultrasonography in, 817–819
of pancreas
MRCP in, 746–747
ultrasonography in, 826–828
of small intestine
computed tomography in, 793–794
enteroclysis in, 722–724
subepithelial, endoscopic ultrasonography in, 873–874
ultrasonography in, 829

Tumor necrosis factor, inhibitors of, for inflammatory bowel disease, 86–88

Turcot syndrome
clinical features of, 1108, 1110–1111, 1115
genetics of, 1108

Twin studies, of inflammatory bowel disease, 64–65

Tyrosinemia, hereditary, hepatocellular carcinoma risk in, 649

U

Ulcer(s), in Crohn's disease, 101–103, 121–122, 136–137

Ulcerative colitis
age of onset of, versus cancer risk, 240–241
cancer in. *See* Cancer, in ulcerative colitis.
clinical features of, in pediatric patients, 279
complications of, radiography of, 99–101
diagnosis of, 267–268, 279–281
differential diagnosis of, 140
distal, 157, 186–187
duration of, versus cancer risk, 240
dysplasia in, 100, 412, 1136–1137
environmental factors in
appendectomy, 26
breast-feeding, 31
diet, 28–31
genetic factors interacting with, 67
hygiene, 31
in pediatric patients, 276–277
nonsteroidal anti-inflammatory drugs, 32
occupation, 31–32
seasons, 32
tobacco use, 21, 23–25
epidemiology of, **1–20,** 63
age of onset, 10–11
challenges in, 1–2
ethnic differences in, 11–12
gender distribution in, 10

Ulcerative colitis (*continued*)
incidence of, 2–10
prevalence of, 2–10
racial differences in, 11–12
temporal trends in, 2–10
exacerbations of, enteric pathogens in, 52
extraintestinal manifestations of. *See* Inflammatory bowel disease, extraintestinal manifestations of.
fertility in, 266
fulminant, 99–100, 158
functional bowel disease with. *See* Functional bowel disease.
genetic factors in, 64–69, 275–276, 310
immunology of. *See* Immunology, of inflammatory bowel disease.
left-sided, 186–187, 238–240
magnetic resonance imaging in, 97–99, 280–281
natural variation in, 138–139
pancolitis in, 157, 187, 238–239
pathogenesis of, microbial factors in. *See* Microbial factors, in inflammatory bowel disease.
pathology of
in atypical presentations, 137–140
in natural variation, 138–139
pseudopolyps, 139–140
treatment effects on, 140
versus Crohn's disease, 133–137
pregnancy and, 266–267
primary sclerosing cholangitis with, 101, 129–130, 241–242
proctitis in, 185–186
pseudopolyps in, 139–140
radiography of, 93–101
barium studies, 94–96
computed tomography, 96–97
in complicated disease, 99–101
magnetic resonance imaging, 97–99, 280–281
versus Crohn's disease, 114–115
severe-to-fulminant, 187–188
severity of, versus cancer risk, 240
skip lesions in, 139
steroid-refractory, 188–189
surgical treatment of, **219–235**
colectomy with ileorectal anastomosis in, 223–224
indications for, 220–221
proctocolectomy with continent ileostomy in, 225
restorative proctocolectomy in, 226–232
subtotal colectomy with ileostomy in, 222–223
total proctocolectomy with Brooke ileostomy in, 224–225
treatment of, **147–166**
aminosalicylates in, 147–150
antibiotics in, 54–55, 152–153
corticosteroids in, 150–152
distal, 157, 186–187
fulminant, 158
heparin in, 155–156
immunomodulators in, 153–155
in pancolitis, 157, 187
in pregnancy, 268–271
in proctitis, 185–186
left-sided, 186–187
maintenance, 158
nicotine in, 155
pathology modification in, 140
probiotics in, 55–56, 156, 159
severe-to-fulminant, 187–188
short-chain fatty acids in, 156
steroid-refractory, 188–189
surgical. *See* Ulcerative colitis, surgical treatment of.
versus Crohn's disease, 114–115, 121–124

Ultrasonography, **809–833**
contrast agents for, 811
Doppler, 810–811
endoscopic. *See* Endoscopic ultrasonography.
in Budd-Chiari syndrome, 814–815
in colorectal cancer staging, 874–875
in Crohn's disease, 110, 130
in esophageal cancer, 880–882
in hepatocellular carcinoma, 651–652
intraoperative, 830
of biliary tract, 821–824, 878
of gallbladder, 820–821
of gastrointestinal tract, 828–829
of liver, 811–820
of pancreas, 824–828, 877
personnel performing, 810

Uropathy, obstructive, in inflammatory bowel disease, 319

Ursodeoxycholic acid
for colorectal cancer prevention, 608, 1141
for primary sclerosing cholangitis, 333–334

Uveitis, in inflammatory bowel disease, 317

V

Vacuolating toxin A, as *Helicobacter pylori* virulence factor, 519, 523

Vagal nerve injury, in antireflux surgery, S100

Vagovagal reflex, in lower esophageal sphincter control, S12–S16

Variceal bleeding, endovascular intervention for, 701–708

Vasoactive intestinal peptide, tumors secreting, computed tomography in, 897

Vasoconstrictive therapy, endovascular, for gastrointestinal hemorrhage, 702–703, 709

Vasopressin, endovascular, for gastrointestinal hemorrhage, 702–703

Vegetables, for colorectal cancer prevention, 595–596, 602, 928–929

Vena cava, inferior, obstruction of, ultrasonography in, 814–815

Villin protein, in esophageal adenocarcinoma, 470–471

Villous adenomas, colonic, 409–410

Virtual colonoscopy, 578–579, **751–760, 1045–1060**
computer-aided diagnosis in, 1056
contrast for, 1051–1053
cost of, 1058
definitions in, 1045–1046
extracolonic findings in, 758, 1055
historical background of, 751–752
image acquisition in, 1046–1049
image evaluation in, 1049
in incomplete colonoscopy, 757–758, 1050–1051
in total body scanning, 1058
interpretation time in, 1055
limitations of, 1053–1055
patient satisfaction with, 1056
preparation for, 753, 1046
reliability of, 754–756
scanning parameters for, 1047–1048
technique for, 752–753, 1050–1053
versus other imaging techniques, 1057
without contrast, 1050–1051

Vitamin(s), for colorectal cancer prevention, 577, 597–598, 600, 602–603, 984

Vitamin C, for colorectal cancer prevention, 600, 930, 984

Vitamin D
deficiency of, in inflammatory bowel disease, 314
for colorectal cancer prevention, 597

Vitamin E, for colorectal cancer prevention, 598, 930, 984

Volvulus, colonic, computed tomography in, 803

W

Warts, anal, as precursor lesions, 412–413

Weight
colorectal cancer risk and, 590–592
esophageal adenocarcinoma risk and, 433

Wet sandpaper appearance, of inflammatory bowel disease, 122

Wilson disease, hepatocellular carcinoma in, 648–649

Wnt signaling pathway, in carcinogenesis, 384–385

Z

Zollinger-Ellison syndrome, gastric dysplasia in, 406–407